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Abstract
An elevated plasma concentration of homocysteine, a sulfur-containing amino
acid derived from methionine, has been recognized as an independent risk factor for tbe
development of vascular discase (Kang et a/., 1992). Methionine is adenylated by
methionine adenosyltransferase to form S-adenosylmethionine, an important biological
methyl donor. Numerous methyltransferases catalyze the transfer of a methyl group from
S-adenosylmethioninc to a methyl acccptor, producing a methylated product and S-
adenosylhomoeysteine which is subsequently hydrolysed to fonn adenosine and
homocysteine. Homocysteine has several possible fates: I) remetbylation to fonn
methionine via either the cobalamin-dependent methionine synthase (using NS•
methyltetrahydrofolate as a methyl donor) or betaine:homocysteine methyltransferase
(using betaine as a methyl donor); 2) catabolism by the transsulfuration pathway,
ultimately fonning cysteine; 3) export to the extracellular space. Two vitamin B6-
dependent enzymes comprise the transsulfuration pathway: cystathionine j3-synthase,
which condenses homocysteine with serine to form cystathionine, and cystathionine y-
lyase, which cleaves cystathionine to cysteinc, NH4"'" and n-ketobutyratc.
Altered flux through the remethylation or transsulfuration pathways as a result of
genetic mutations or impaired vitamin status has been shown to affect plasma
homocysteine levels (Ubbink el al., 1993; Kluijtmans et al., 1999). In recent years it has
also become apparent that certain honnones can affect homocysteine metabolism. It has
been shown that hypoth)'Toid patients tend to have elevated plasma homocysteine and that
these levels are normalized when thyroid levels are restored by thyroxine treatment
(Nedrebo el at., 1998; Hussein et al., 1999). Altered homocysteine metabolism has been
observed in diabetes mellitus. Diabetic patients (Types I and 2) with signs of kidney
dysfunction (i.e. elevated creatinine levels) lend to have increased plasma homocysteine
(Hultberg et al., 1991). However in the absence of rcnal dysfunction, Type I diabetic
patients exhibit decreased plasma homocysteine relative to nonnal subjects (Robil1on et
at., 1994). In this thesis we investigated the honnonal regulation of homocysteine
metabolism in rats in hope that we could illuminate a possible mechanism for altered
plasma homocysteine levels in human hypothyroidism and Type I diabetes mellitus.
In Chapter 3, hypothyroidism was induced in one study by addition of
propythioumcil (PTll) to the drinking water for 2 weeks. In a second study,
thyroidectomized and sham-operated rats were used with thyroid honnone replacement
via mini-osmotie pumps. Unlike the human hypothyroid patients, both groups of
hypothyroid rats exhibited decreased total plasma homocysteine (30% in PTU rats, 50%
in thyroidectomized rats) versus their respective controls. Thyroid replacement
nonnalizcd homocysteine levels in the thyroidectomized rat. Increased activities of the
hepatic trans-sulfuration enzymes were found in both models of hY\Xltbryoidism. These
results provide a possible explanation for the decreased plasma homocysteine
concentrations. The hypothyroid rat cannot be uscd as a model to study homocysteine
metabolism in hypothyroid patients.
The purpose of our second study (Chapter 4) was to investigate homocysteine
metabolism in a type 1 diabetic animal model and to examine whether insulin plays a role
in its regulation. Diabetes was induced by intravenous administration of streptozotocin
iii
(l00 mgfkg) to rats. Depending on the experiment, we observed a 30-70 % reduction in
plasma homocysteine in the untreated diabetic rat. Treatment with insulin of the diabetic
rat raised plasma homocysteine concentrations. Transsulfuration and remethylation
enzymes were measured in both liver and kidney. We obsen'ed an increase in the
activities of the hepatic transsulfuration enzymes (cystathionine ~-synthase and
cystathionine y-lyase) in the untreated diabetic rat. Insulin treatment normalized the
activities of these enzymes. The renal activities of these enzymes were unchanged as was
the proportion of plasma homocysteine metabolized by the kidney. These results suggest
that insulin is involved in the regulation of plasma homocysteine concentrations by
affecting the hepatic transsulfuration pathway.
The increased hepatic cystathionine ~-synthase activity in the untreated-diabetic
rat was associated with elevated mRNA levels. Similar to its activity, cystathionine ~­
synthase mRNA levels were reduced by insulin administration. To further investigate the
regulation of cystathionine ~-synthasc we incubated rat hepatoma cells (H4IIE) with
various hormones. Cystathionine ~·synthase mRNA, protein, and activity were induced in
triamcinolone stimulated H411E cells. This induction was prevented by insulin incubation.
CPT-cAMP, an analogue o(cAMP, also induces cystathionine ~-synthase mRNA levels
in cultured cells. Co..incubalion of insulin with CPT-cAMP prevents any increase in
mRNA levels. These experiments provide evidence of the direct regulation of
cystathionine ~.synthase by insulin and its counter-regulatory hormones.
Given. the broad regulatory effects of glucagon on amino acid mctaoolism
and the fact that plasma glucagon levels arc often elevated in Type 1 diabetes we
investigated the effect of glucagon on homocysteine metabolism in the rat (Chapter 5).
Male Sprague Dawley rats were treated with glucagon (4 mglkg/day in three divided
doses) for 2 days while control rats received vehicle injections. Glucagon treatment
resulted in a 30% decrease in total plasma homocysteine and increased hepatic activities
of glycine N-mcthyltransferase, cystathionine J3-synthase and cystathionine y-lyase.
Enzyme activities of the rcmethylation pathway were unaffected. The 90% elevation in
activity of cystathionine J3-synthase was accompanied by a two-fold increase in its mRNA
level. Hepatocytes prepared from glucagon-injected rats exported less homocysteine,
when incubated with methionine, than did hcpatocylcs of saline-treated rats. Flux
through cystathionine J3.synthase was increased five-fold in hepatocytes isolated from
glucagon-treated rats as determined by production of 14C02 and 1.14C-a-ketobutyrate
from L-[1-14C]methionine. Methionine transport was elevated two-fold in hepatocytes
isolated from glucagon-treated rats resulting in increased hepatic methionine levels.
Hepatic concentrations of S-adenosylmethionine and S-adenosylhomocysteine, allosteric
activators ofcystathionine tJ-synthase, were also increased following glucagon treatment.
These results indicate that glucagon can regulate plasma homocysteine through its effects
on the hepatic transsulfuration pathway.
This thesis provides clear evidence that glucagon lowers plasma homocysteine
while insuLin has the opposite effect. The mechanism for this reciprocal regulation has
been outlined in detail. Taken together, it is clear that these metabolic hormones can be
very important in controlling plasma homocysteine levels and that the liver is Ihe site of
this hormonal regulation.
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Chapter I: Introduction
1.1 Historical Perspective
The study of sulfur amino acids began in 1810 when Wollaston isolated
"cystic acid" from bladder stones taken from a human patient (Finkelstein, 2000).
Two decades later, "cystic acid" was detcnnined to be cysteine. However, a century
would pass until du Vigneaud would chemically synthesize homocysteine from
mcthionine.
The events leading to the iliscovery of homocysteine are fascinating. Du
Vigncaud was intrigued by the chemical nature of insulin, which had been isolated by
Banting and Best in 1922. His particular interest was of the chemical nature of sulfur
in this protein. In his early work he concluded that cysteine could not account for the
entire sulfur comem of insulin; therefore he started experiments on the newly isolated
amino acid, methionine. In 1932, du Vigncaud reported that homocysteine was
fonned when methionine reacted with concentrated acid (Butz and Du Vigneaud,
1932). Having isolated homocysteine, du Vigneaud and his colleagues began
nutritional and metabolic studies using the three sulfur-containing amino acids. This
was the beginning of the study of sulfur amino acid metabolism and in the following
decades the biochemical intcnnediates, enzymes, and regulators would be discovered
and characterized. Today we are still investigating the factors regulating sulfur amino
acid metabolism, as is evident from this thesis. The importance of du Vigneaud's
discovery cannot be overstated; however there is a delightful footnote to his work. He
misinterpreted his initial findings on insulin: cysteine does account for all the sulfur
in insulin!
1.2 Overview
Methionine is an indispensable, sulfur-containing amino acid and, as such, in
mammals its dietary availability is essential for the nonnal growth and metabolism of
animals. Methionine is involved in protein synthesis, in the synthesis of S-
adenosylmethionine, an important biological methyl donor and intennediale in
polyamine synthesis, and in tbe fonnation of homocysteine. The conversion of
homocysteine back to methionine is necessary for the catabolism of choline and
betaine, and in the recycling of intracellular folates, whilc the catabolism of
homocysteine yields cysteine (a substrate for protein and glutathionc synthesis) wbich
is a precursor of taurine (important in bile synthesis). The role of sulfur amino acids
in cellular processes is indced impressive.
Figure I-I summarizes the reactions involved in methionine metabolism. In
the first step dietary methionine is activated to thc high.energy sulfonium compound,
S-adenosylmethionine (SAM), via the enzyme methionine adenosyltransferase. S-
adenosylmethionine is the primary biological methyl donor and is a substrate for
hundreds of transmethylation reactions. For example, SAM can methylate DNA,
phospholipids, and guanidinoacetate, fonning S-adenosylhomocysteine and a
methylated product. S-adenosylhomocysteine is then hydrolysed to adenosine and
homocysteine. Homocysteine has many metabolic fates: I) it can be remethylated
back to methionine via methionine synthase (using methyltetrahydrofolate as a
methyl donor) or via betaine:homocyslcine methyltransferase (using betaine as a
methyl donor); or 2) it can be catabolized 10 cysteine via the Inmssulfuralion pathway
Figure I.t: Methionine/Homocysteine metabolism in mammals.
The numbers beside the arrows represent the following enzymes: 1- Methionine
adenosyltransferase, 2- Glycine N-methyltransfcrasc, 3- S-adenosylhomocysteine
hydrolase, 4- Methionine synthase, 5- Methylenetetrahydrofolate reductase, 6-
Betaine:homocystcine methyltransferase, 7- Cystathionine I}-synthase, 8-
Cystathionine y-lyase, 9- various transmethylation reactions.
"i5
which contains two vitamin 86-dependent enzymes, cystathionine p-synthase and
cystathionine y-lyase; or 3) it can be exported oul of the ccll.
As alluded to above, the metabolism of methionine and homocysteine is the
combination of two distinct metabolic sequences, the methionine cycle and the
transsulfuration pathway. All enzymes involved in methionine metabolism arc found
within Ihe cytoplasmic compartment; however tbe tissue profiles of these enzymes
are very different. Human and ral livers possess significant activities of all the
enzymes shown in Figure 1.1, which is not surprising given the importance of hepatic
amino acid metabolism. Besides the liver, only the pancreas and kidney have
significant activities of the transsulfuration pathway (Finkelstein, 1990). Unlike the
transsulfuration pathway, Ihe methionine cycle is ubiquitous in nature. All cells
contain methionine synthase and melhylenetetrahydrofolate reductase; however
betaine:homocysteine methyltransferase, the other remclhylation enzyme, is not as
prevalent. In humans, betainc:homocysteine methyltransferase can be found in liver,
brain and kidney (Finkelstein, 1974). Unlike humans, rats do nol have renal betaine-
homocysteinc methyltransferase (Delgado-Reyes et ol., 2001).
It is clear that melhionine metabolism is important in every tissue. Given that
most of the experiments have utilized liver tissue and that the liver has a full
complement of relevant enzymes, this introduction will focus mainly on hepatic
melhioninelhomocysleine metabolism; however, other tissues will be mentioned
when appropriate. The discussion will begin with a description of the methionine
cycle and the transsulfuration pathway and the interactions between them. The main
theme of this thesis is the regulation of homocysteine metabolism, so the regulation of
individual enzymes and of flux through pathways will be highlighted. The discussion
begins at the gateway of methionine metabolism, the synthesis of S-
<ldenosylmethionine.
1.3 Methionine Adeoosyltransferase
Methionine adenosyltransferase, or S-adenosylmethionine synthase, (EC
2.5.1.6, Figure 1.1- reaction I) is a ubiquitous enzyme that catalyzes the formation of
S-adenosylmethioninc from ATP and methionine. The synthesis of SAM is achieved
via two sequential reactions: in the first reaction, the methionine sulfur
nucleophilically attacks the C5' carbon of ATP, producing an enzyme-bound SAM
and tripolyphosphate; secondly, the tripolyphosphate is hydrolysed to pyrophosphate
and orthophosphate, a step which is rate-limiting for the overall sequence and is
required for product release (Markham el al., 1980; Sanchez del Pino el al., 2002).
Two genes, MATtA and MAT2A, encode for the c<ltalytic subunil of
methionine adenosyltransferase (Alvarez et al., 1993). MATtA is expressed only in
adult liver, whereas MAT2A is expressed in all non-hepatic tissues. In addition,
MAT2A is found in fetal liver and is replaced by MATI A during organ maturation.
The two MAT genes encode for different isozymes of the catalytic subunit, named a,
which have a high degree of homology (approximately 85%). MATtA gcne encodes
for the al protein while the MAT2A gene encodes for the a2 protein (Kotb el al.,
1997).
In the adult liver, MATIA gives rise to two isofonns of methionine
adenosyltransferase: a 210 kDa a I tetramer (MAT J) and a 110 kDa a 1 dimer (MAT
III) (Sullivan and Hoffman, 1983). MAT I displays Michaelis-Menten kinetics with a
Km for methionine of 3-40 11M and is allosterically inhibited by the reaction product
S-adenosylmethionine.ln contrast, MAT 1lI is labelled the "high Km" isofonn with its
Kmfor methionine ranging between 0.03-1.4 mM, and is allosterically activated by S-
adenosylmethionine (Finkelstein, 1990). Thus the reaction velocity of MAT III
increases in response to elevated methionine and S-adenosylmethionine levels, which
permits rapid clearance of excess methionine in the liver. The regulation of hepatic
MAT will be discussed in later sections.
The extrahepatic MAT 11 is described as the "low Km" enzyme with values for
methionine ranging from 4 to 23 IlM; like MAT I, S·adcllosylmcthioninc inhibits the
reaction (Finkelstein, 1990). Unlike the liver enzymes, MAT II is a heterodimer OfU2
(catalytic) and ~ (regulatory) subunits. When the ~ subunit, the gene product of
MATIB, associates with the a subunit, it alters its kinetic properties thus making
MAT II more susceptible to inhibition by S-adcnosylmethionine (Halim et al., 1999).
Stimulation ofT cells results in up regulation ofMAT2A gene and down·regulation
of MAT2S gcnc. Thcse conditions favour increased fonnation of a2 oligomers. This
form of MAT II has a 3-fold higher specific activity and results in a 6-fold increase in
intracellular S-adenosylmethionine concentrations (LeGros et ai., 1997). Similar
results were observed using a transfected human fibroblast cell line (Halim et al.,
1999). Indeed, differential expression of the MAT II ~ subunit may be very important
in regulating MAT activity in cxtrahepatic cells and may represent a mechanism that
modulates S-adenosylmethioninc concentrations during different stages of growth and
development
1.4 $-Adenosylmethionine and transmethylation reactions
The liver is the site of 85% of all methylation reactions in the body (Wyss and
Walliman, 1994). Given this infonnation it is nol surprising that the formation of S-
adenosylmethionine (SAM) is vital for nonnal function. S-adenosylmethionine is the
primary methyl donor in virtually all biological methylation reactions with the
exception of those involved in the methylation of homocysteine, and participates in a
wide range of cellular processes through the methylation of nucleic acids, proteins,
phospholipids, and small moleculcs (Stipanuk, 1986). Alternatively, the propylamine
moiety of SAM can be used in Ihe synthesis of polyamines. Despite their important
biological function, it is estimated that only lO% of the available S-
adenosylmcthionine is utilized in this sequence (Mudd and Poole, 1975). Since, S-
methylthioadenosine can be recycled back to methionine it is assumcd that polyamine
synthesis has a minimal effect on cellular methionine metabolism (Backlund and
Smith, 1981).
In a series of balance studies Mudd and Poole (1975) attempted to quantify
the demands of transmethylation reactions on the availability of S-
adcnosylmethionine. In these studies, humans were fed cysteine-free diets containing
various levels of methionine and choline. As methionine and choline comprised the
dietary methyl group supply, the availability of labile methyl groups could be easily
determined. Their initial findings showed that when males were fed a normal diet the
excretion of creatinine was greater than the dietary supply of methyl groups. From
this key obsclVation it was concluded that de novo synthesis of methyl groups must
be important in humans (Mudd and Poole, 1975). The de novo source of these methyl
moieties is methyltetrahydrofolate which can methylate homocysteine 10 fonn
methionine. Further experiments showed that male subjects, under normal dietary
conditions, cycled the homocysteinyl moiety between methionine and homocysteine
approximately 1.9 times before converting it to cystathionine. This value was 1.5 for
female subjects. In essence, these studies indicated that approximately half of the
homocysteine was converted to cystathionine with the remainder being rcmethylated.
However, when humans were fed a diet low in methionine and choline, each
homocysteinyl moiety, on average, passed through the methionine cycle at least 4
times in males and 3 in females. These studies suggested that the dietary content of
methyl donors influence the de novo synthesis of methyl groups (Mudd and Poole,
1975). Specifically, when methyl groups are limiting, the remethylation pathway is
activated; however, when methionine is in excess catabolism via the transsulfuration
pathway is favoured.
104.1 Glycine N-metbyltransfcrase
The results from Mudd and Poole's studies suggest an important role for
glycine N-methyltransferase in the metabolism of excess methionine. Glycine N-
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methyltransferase (GNMT, EC 2.1.1.20, Figure 1.1- reaction 2) catalyses the
methylation of glycine, by S-adenosylmethionine, to form sarcosine and S-
adenosylhomocysleine (SAH). Sarcosine, which has no other known physiological
role, may be transported into the mitochondrion where it is converted, by sarcosine
dehydrogenase, to glycine and methylenetetrahydrofolate. Thus by the coupled action
ofGNMT and sarcosine dehydrogenase, SAM may be converted to SAH without the
nel consumption of glycine (Heady and Kerr, 1973). GNMT is found predominantly
in liver of mammals (Blumenstein and Williams, 1960), comprising 1-3% of soluble
protein; however high levels are also found in kidney cortcx and pancreatic exocrine
cclls (Heady and Kerr, 1973; Kerr, 1972).
GNMT can be distinguished from other methyltransfcrases by its protein
structure and kinetic properties. GNMT is an oligomeric prolcin consisting of 4
identical 32 kDa subunits, and displays Michaelis-Menten kinetics with respect to
glycine with a Km around 230 ~ (Ogawa and Fujioka, 1982; Ogawa et af., 1997).
However, S·adenosylmethioninc exhibits sigmoidal kinetics with a [5]0.5 equalling 60
IlM (Ogawa and Fujioka, 1982). It should be noted that the [S]o.5 (SAM) is higher for
GNMT than for thc other methyltransfcrase reactions which vary belween 10-20 IlM
(DueITe el ai., 1977; Hoffman et al., 1979). Furthennore, unlike the otber
methyltransferases, GNMT is not inhibited by S-adenosylhomocysteinc. Given these
kinetic and regulatory properties, along with its abundance in liver cells, GNMT may
serve as a mechanism to metabolize SAM when methyl supply is in excess. Likewise,
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when SAM is limiting, the activity of GNMT is reduced, thus preserving the valuable
methyl supply.
1.5 8-adenosylhomocysteine hydrolase
As described previously, the reaction product (S-adenosylhomoeysteine)
inhibits most biological transmethylation reactions. For this reason, the removal of
SAH is essential for normal cellular function. S-adenosylhomocysteine hydrolase (EC
3.3.1.1, Figure 1.1- reaction 3) is responsible for the intracellular removal of SAH by
converting it to homocysteine and adenosine. The enzyme is ubiquitous in
mammalian tissues and is composed of 4 identical 47 kDa subunits (Coulter-Karis
and Hershfield, 1989).
The hydrolySIS of SAH is a reversible reaction; in fact, the equilibrium (Kat '"
IO~ M) greatly favours SAH synthesis (Stipanuk, 1986). However, SAH hydrolysis
nonnally occurs, in vivo, due to the removal of homocysteine and adenosine.
Intracellular elevation of either product results in accumulation of SAH, which has
far-reaching consequences. The ratio of SAM 10 SAH, which is normally around 5,
may be vel)' important in regulating transmethylation reactions (Hoffman et al.,
1979). For example, when SAMISAH ratios approach 2, DNA and histone
methyltransferases inhibited, whereas phosphotidylethanolamine
methyltransferase is inhibited when the SAMISAH ratio approaches 3 (HolTman et
al., 1979). Although melhyltransferascs behave differently at various SAM/SAH
ratios, it is clear that an elevation of SAH will inhibit at least some methyltransferase
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reactions and its removal is imperative for nonnal ccUuhlr function. This
phenomenon can be obsen'ed in patients with adenosine deaminase deficiency, who
cannot deaminate adenosine to inosine (Hershfield et al., 1985). The elevation of
adenosine inhibits SAH hydrolase activity resulting in a multitude of problems. The
ensuing elevation in SAH levels inhibits transmethylation reactions, while the
decreased cysteine production, via the transsulfuration pathway, disrupts glutathione
synthesis and perpetuates cellular oxidative damage (Atmaca and Fry, 1996).
Two other mechanisms can remove intracellular SAH. First, 8AH can bind to
specific intracellular proteins. thus becoming kinetically inactive (Svardal and
Ueland, 1987). Secondly, elevated SAR may also be exported out of the cell (Duerre
et al., 1969; Hoffman et al.• 1980).
J.6 Remethylation of Homocysteine
The importance of homocysteine removal for the nonnal functioning of
methyltransferase reactions was outlined in the previous section. The cell has three
major routes to remove intracellular homocysteine: I) it can export it out of the cell;
2) it can irreversibly catabolise it via the transsulfuration pathway to fonn cysteine; or
3) it can remethylate it back to methionine. The remethylation of homocysteine can
be catalyzed by methionine synthase or by betaine:homocysteine methyltransferase,
representing the conservation of the carbon skeleton and sulfur alom from the original
methionine molecule.
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1.7 Methionine Synthase
Methionine synthase (EC 2.1.13, Figure 1.1- reaction 4), a cytoplasmic
enzyme which is widely distributed in mammalian tissues, is responsible for the
methylation of homocysteine, by methyltetrahydrofolate, to form methionine and
tetrahydrofolate (Xue and Snoswell, 1985). An enzyme+bound cobalamin moiety is
vital for methionine synthase activity since it facilitates the methyllransfer (Chen et
al., 1995). Catalytic amounts of S-adenosylmethionine are also required to maintain
cobalamin in its active fonn (Burke et aI., 1971).
The importance of methionine synthase in homocysteine metabolism was
confirmed in human patients with inborn errors of metabolism that reduee methionine
synthase activity (Fenlon and Rosenberg, 1989). The consequence of such mutations
were elevated levels of plasma homocystcine and low plasma mcthionine (van der Put
et al., 1997). Methionine synthase may also be inactivated in animals by exposure to
nitrous oxide, resulting in decreased tissue levels of methionine and SAM, and
impaired transmethylation reactions (Lumb el al., 1980).
Methionine synthase is also involved in folate metabolism. Folate is essential
for the biosynthesis of both purines and pyrimidines; thus, a folate deficiency
compromises the cell's ability to synthesise DNA and RNA (Shane and Stokstad,
1985). This can have devastating effccts on quickly dividing cells, such as bone
marrow (Koury and Home, 1994), often resulting in macrocytic anemia (Matthews el
al., 1990). Cells obtain folate from the blood principally in the fonn of
methyltetrahydrofolate. Only methionine synthase can use this form of folic acid
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(Shane, 1989). The conversion of methyl-THF to THF results in the formation of a
more useable form of cellular folate, which can be polyglulamated and retained by the
cell (Shane and Stokstad, 1985). When methionine synthase activity is impaired,
either by vitamin 812 deficiency or mutation, methyltetrahydrofo[ate accumulates at
the expense of other cellular folates (Shane, 1989). This condition is called the "folate
trap", since, under nonnal cellular conditions, methyltetrahydrofolate cannot be
oxidized by mcthy[enetctrahydrofolatc reductase (Finkelstcin el at., 1978). The
decrea."e in functional cellular folate also explains why elinical symptoms of folate
and vitamin 812 dcficiency are similar.
1,8 MethyJenetetrahydrofolate Reductase
Remethy[ation of homocysteine by methionine synthase is dependent on the
availability of methyltetrahydrofolate, which can be obtained from the circulation or
from pre-existing cellular folates. Methylenetetrahydrofolate reducta"e (MTHFR,
E.C.1.7.9.9.5, Figure 1.1- reaction 5) catalyses the NADPH-dependent reduction of
5',IO'·methylenetctrahydrofo[ate to mcthyltetrahydrofolatc, represcnting the only
methylletrahydrofolate-generating reaction in the cell (Green el al.• 1988). This
enzyme is a dimer of identical 77 kDa subunits containing a non-covalently bound
FAD (Daubner and Matthews, 1982). Tryptic cleavage of the subunit produces a N·
tenninal 40 kDa catalytic region and a 37 kDa regulatory region (Matthews et al.,
1984).
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In recent years, there has been an extensive search for mutations in the human
methylenelClrahydrofolate reductase gene. Several mutations associated with severe
enzyme deficiency in humans have been identified; two such mutations arc
Argl57Gln and Thr227Mct (Matthews et al., 1998). One polymorphism, Ala222Val,
has a high incidence in humans (Frosst et aL, 1995). Patients homozygous for this
polymorphism have reduced enzyme activity in fibroblasts, and the enzyme
demonstrates increased susceptibility to heat inactivation (Engbersen et aL, 1995).
This mutation is of importance since il has been linked to increased risk for neural
tube defects (Whitehead et al., 1995), and development of cardiovascular diseases
(Engbertsen et al., 1995), although the latter correlation is under dispute (deFranchis
et al., 1996). These patients seem to be very sensitive to folate status, with folate
deficient diets resulting in massive increases in plasma homocysteine (Jacques et al.,
1996). The Ala222Val mutation may result in loss of enzyme-bound FAD (Matthews
et a/., 1998), a phenomenon that may be prevented by folate supplementation
(Yamada et al., 2001). Studies on a mutated bacterial enzyme (Matthewset al., 1998)
and human mutants (Yamada et a/., 2001) are consistent with tbis possibility. Thus
the decrease in activity in cells from these patients may reflect the presence of
inactive apo-enzyme.
1.9 Betaine-Homocysteine Methyltransferase
The second enzyme that methylates homocysteine to give methionine is
betaine-homocysteine methyltransferase (BIIMT; E.C. 2.1.1.5, Figure 1.1- reaction
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6). In this reaction, betaine donatcs a methyl group to homocysteine fonning
dimethylglycine and methionine, respectively. This reaction is required for the
irreversible oxidation of choline, the metabolic precursor of betaine. The enzyme is a
hexamer of 45 kDa subunits with each monomer containing a Zn-binding site
(Garrow, 1996). The kinetics of the rat liver enzyme have been investigated. Km
values for homocysteine and betaine wcre reported as 15-20 and 50-60 11M,
respectively (Stipanuk, 1986). In contrast to methionine synthase, BHMT is not
widely distributed in mammalian tissues. In humans, BHMT can be found at high
activity in liver and at lower activity in brain and kidney (Finkelstein, 1974). Unlike
humans, rats do nol have renal betainc-bomocysteine methyltransferasc.
1.10 Transsulfuratlon Pathway: Cystathionine II-Synthase
The carbon and sulfur groups of methionineJbomocysteine are removed from
the methionine cycle via the transsulfuration pathway. The first reaction in this
sequence is mediated by the vitamin B6-dependent and heme-containing enzyme,
cystathionine f3--synthasc (CBS; E.C. 4.2.1.22, Figure 1.1- reaction 7), which catalyses
the condensation reaction of homocysteine and serine to fonn cystathionine. The
prcsence of heme is essential for activity (Kery et al .• 1994). This condensation
reaction may be reversed if homocysteine is rapidly removed; however, under
physiological conditions the equilibrium favours cystathionine fonnation (Finkelstein,
1990).
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Mammalian cystathionine fl·synthase is a tetramcric protein of identical 63
kDa subunits with Km values for serine of about I mM and for homocysteine ranging
from I to 25 mM (Taoka el al., 1998). Although quite a range, it is clear that these
values far ex.ceed those of tbe remethylation enzymes. In contrast to the methionine
cycle enzymes, cystathionine l3-synthase is only found in a few tissues. The liver has
the highest level of activity, followed by the pancreas, kidney and small intestine.
Abnormal synthase expression has been extensively studied in humans.
Cystathionine l3-synthasc deficiency is the most common disorder of sulfur amino
acid metabolism, with an incidence of 1:75000 (Mudd and Levy, 1978). This inborn
error was first reported in 1963 during screening tests of mentally retarded patients in
Nonhem Ireland (Carson el al., 1963). Since that first observation, over 100 distinct
mutations in the CBS gene have been reported worldwide. In a survey of 630
bomocysteinuric patients, Mudd el al. (1985) showed that 50% of the patients
displayed a large decrease in homocysteine concentration associated with increased
CBS activity when they were given pharmacological doses of pyridoxine. This
suggests that about half of the mutations result in decreased pyridoxal-S-phosphate
binding affinity; thus increased concentration ofthc co-factor is required for activity.
Studics using tissue samples from vitamin B6.nonresponsivc patients found that
certain mutations cause CBS to fold improperly because it cannot bind heme (Janosik
el al., 2001). Furthermore, abnonnally folded CBS disfavours tetramer formation and
makes the mutant prone to subunit aggregation, thus inactivating the enzyme.
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1.11 Cystathionine y~Lyase
The last enzyme involved in the catabolism of methionine to cysteine,
cystathionine y-lyase (CyL; EC 4.4.1.1, Figure \.I-reaction 8), catalyzes the
conversion of cystathionine into cysteine, a-ketobutyrate and anllllOnia. Rat
cystathionine y-Iyase is composed of four 43 kDa subunits and its activity is
pyridoxal-5-phospbate dependent (Braunstein and Goryachenkova, 1984). The Km for
cystathionine has been reported to be in the range of 0.3 to 3.5 mM. The liver has the
highest activity of cystathionine y-Iyase, whereas the kidney and pancreas exhibit
approximately balfthe hepatic level (Nishi et al., 1994).
It has been shown that cystathionine y-Iyase protein and activity are absent in
fetal fiver (Gaull el 01., 1972; Stunnan et al., 1970). The rate of glutathione synthesis
from methionine is considerably lower in fetal compared with adult hepatocytes, and
thus can be anributed to the low enzyme activity (Heinonen, 1973). Although
cystathionine y-Iyase activity is absent in fetal liver, its mRNA can be detected as
early as the nineteenth gestational week (Levonen et al., 2000). The reason for the
discrepancy between mRNA and enzyme activity is currently unknown. However, it
has been suggest that posttran5criptional regulation, rather than the presence of an
inhibitor or improper protein folding, is thc most plausible explanation (Lovenen el
aJ., 2000).
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1.11 Regulation of Homocysteine metabolism
Early studies on both animals and human patienls with inborn errors of
metabolism illustrated thai intcrconvcrsion of methionine and homocysteine was a
cycle, with irreversible fCmoval of homocysteine from the cycle achieved by
cystathionine J3-synthasc. The balance between the two pathways ensures tbat
sufficient methionine is available for protein synthesis and SAM-dependent
methylation reactions while preventing methionine toxicity and supplying adequate
levels of cysteine for glutathione synthesis and other functions. In his early
experiments, Finkelstein (1978) provided evidence for the regulation of these
pathways. In a delicate experiment he measured the radioisotope disappearance of
eH-methyl/5S]methionine in liver slices taken fTom mts fed either a 3.5% or 55%
casein diet. From this experiment, Finkelstein could measure the half-life of
methionine and the proportion of homocysteine catabolised by the transsulfuration
pathway. The half-life of 3H_methyl groups was reduced from 9.3 to 4.8 minutes
when animals were fed a high protein diet. This change in half-life corresponded to
an increased conversion of homocysteine to cystathionine, from 10 % in the control
diet to 70% in the high-protein. These data obtained in vitro validated the human
methylation studies (discussed in section 1.4) completed just a few years earlier by
Mudd and Poole (1975). The next section discusses how competing pathways are
controlled in tandem to achievc metabolic balance between methionine conservation
and catabolism. The two major mechanisms tbat regulate homocysteine metabolism
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are the level of enzyme in the tissue and the kinetic properties of the relevant
enzymes.
1.12.1 Tissue level of enzymes
The liver bas been recognized as an important site for amino aeid metabolism.
With this in mind, it should not be surprising that alterations in dietary methionine,
either by methionine supplementation or increased protein intake, can affecl the tissue
content of the relevant enzymes. This can be clearly seen in rats fed a low (3.5%)
versus high (55%) casein diet. The activities of all hepatic enzymes responsible for
converting methionine to cysteine wcre altcred by methionine excess. The activities
of methionine adenosyhransferase, glycine N-methyltransferase, and S-
adenosylhomocysleine hydrolase were elevated 1-2 fold, while cystathionine 13-
synthase and cystathionine 'Y-lyase were 3-4 times higher in livers taken from rats fed
a high-protein diet (Finkelstein and Mudd, 1967; Ogawa and Fujioka, 1982;
Finkelstein and Harris, 1973). These findings are consistent with the decreased
methyl group half-life and increased transsulfuration flux observed in livcr slices
isolated from high-protein fed rats (Finkelstein, 1978). The behaviour of the
rcmethylation enzymes was quite different from those thaI catabolize methionine.
Methionine synthase was drastically decreased during mcthionine excess, which is
consistcnt with the enzyme's role as a conserver of methyl groups (Finkelstein et a/.,
1971). Methylenetetrahydrofolate reductase activity was unaltered by fluctuations in
dietary methionine (Finkelstein, 1978). Howcycr, bctainc:homocysteine
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methyltransferase activity was elevated in rats fed either a methionine deficient or
supplemented diet. It has been hypothesized that betaine:homocysteine
methyllransferase functions to maintain tissue methionine concentration when intake
is limited and 10 remove homocysteine when methionine is in excess (Finkelstein el
al., 1983). Recently the interactions between dietary methionine and methyl donor
intake (choline and betaine) were investigated with respect to bctaine:homocysteine
methyltransferase. It was found that methionine-deficient diets could elevate levels of
betaine:homocysteine methyltransferase mRNA, protein and activity (Park and
Garrow, 1999). However, maximum betaine:homocysteine methyltransferase
induction was only observed when high levels of betaine or choline were also present
in the diet.
The dietary content of cysteine also affects the hepatic content of enzymes.
Womack and Rose (1941) were the first to demonstrate that cysteine could replace
approximately 70"10 of the dietary requirement for methionine. The enzymatic basis
for the methionine-sparing effect of cysteine was first studied by Finkelstein and
Mudd (1967). They observed that replacement of dietary methionine with cysteine
resulted in marked decrease in the hepatic activity of cystathionine l}-synthase, but
had little effect on the level of remethylation enzymes. The decreased activity of
cystathionine l3-synthase was later shown to occur at the gene level since
cystathionine l3-synthase mRNA levels were reduced in rats fed a low methionine!
high cysteine diet (Yamanoto et aI., 1995).
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1.12.2 Enz)'me kinetics and allosteric regulators
In the long term, altering the flux through a pathway may be achieved by
changing the tissue content of individual enzymes; however the kinetic properties of
the enzymes, their relative affinities for substrates and their response to effectors, can
provide a rapid mechanism for responding to intracellular perturbations.
The enzymes that metabolize methionine and its derivatives can be elassified
according to their Kmvalues (Table 1.1). The methionine "conserving" enzymes have
low Km values and tend to be inhibited by their products. The enzymes in this
category include MAT 1, SAH hydrolase, betaine:homocysteine methyltransferase,
methionine synthase, and methylenetetrahydrofolatc reductase. In contrast, the
methionine "catabolizing" enzymes have relatively high Km valucs, and arc not
inhibited by their reaction product. MAT IiI, cystathionine f}-synthase and
cystathionine y-lyase are included in this group. Furthennore, Glycine N-
methylttansferase can also be considered a member of this group. There arc two
properties that make GNMT ideal for its role in methionine catabolism: it is not
inhibited by S-adenosylhomocysteine; and it produces sarcosine, a non-toxic
recyclable product (Cook et aI., 1989). The "low" Km values of the methionine
"conserving" enzymes and the "high Km" values of the "catabolizing" enzymes
ensure that when methionine is required, homocysteine is conserved; however, when
methyl groups are in excess, flux through the ttanssulfuration pathway is favoured.
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TableLl: Classilleation of methionine metabolizing enzymes
Methionine K.(PM) Methionine Km(mM)
Conserving Catabolizing
Enzvmes Enzymes
MATI Met: 3-40 MATUI Met: 0.03-1.4
SAH hydrolase SAH: 8·60 Cystathionine lJ- Ser: 1.0
synthase Hey: \-25
BHMT HCY: 15-20 Cystathionine y- CYST: 0.3-3.5
Betaine: 50~60 lyase
Methionine HCY: 60 GlycineN~ Gly: 0.23
Synthase methyltransferase SAM: 0.06
MTID'R NotavailabJe
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S-adenosylmethionine and S-adenosylhomocysteine also playa significant
role in regulating the proportion of homocysteine that is remethylated versus the
proportion which is catabolized. The cellular level of S-adenosylmethionine is
dependent on the supply of methionine, as would be expected. As summarized in
Figure 1,2, elevated levels of SAM inhibit betaine-homocysteine methyltransferase
and methylenetetrahydrofolate reductase, which limit~ the availability of
methyltetrahydrofolate, while activating methionine adenosyltransferase III and
cystathionine [i-synthase (Finkelstein and Martin, 1984; Kutzbach and Stokstad,
1971; Finkelstein, 1990). Shan et al. (2001), using site-directed mutagenesis, has
shown that S-adenosylmethionine binds to the C-tcnninal domain of cystathionine fJ-
synthase. The binding of SAM removes the inhibition provided by the regulatory
domain resulting in a decreased Km value for homocysteine and an increase in
specific activity. Taken together, the regulatory effects of elevated SAM promote
transsulfuration flux, while limiting homocysteine remethylation.
Like SAM, S.adenosylhomocysteine levels regulate enzymes involved in
methionine metabolism. The major effect of elevated levels of SAH is inhibition of
transmethylation reactions (Cantoni, 1985). However, SAH may also activate
cystathionin~ fJ-synthase by binding to the same site as SAM (Finkelstein and Martin,
1984). SAH's effect on the remetbylation pathway is less clear. SAH activates
methylenetctrahydrofolate reductase, when SAM levels are nonnal, providing a
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Figure 1.2: Allosteric regulation of methionine metabolism by S-
adenosylmethionine. The positive and negative allosteric regulation sites are
represented by + and - symbols, respectively.
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mechanism for increased substrate production for methionine synthase (Kutzbach and
Stokstad, 1971). However, elevated levels of SAH inhibit methionine synthase.
Furthennore, SAH only regulates betaine:homocysteine mcthyltransferase when
SAM is Donnal (Finkelstein et at., 1974). Clearly, the regulatory effects of SAH necd
additional investigation.
The level of cellular methyltetrahydrofolatc may also act as a metabolic
regulator. Hepatic levels of methyltetrahydrofolate arc inversely proportional to the
availability of methionine. Typically whcn mcthyltetmhydrofolate is elevated,
methionine levels are low and thus need to be conserved (Cook et aI., 1984). In such
a situation methyltetrahydrofolate inhibits glycine N-methyltransferase, thereby
preventing tbe removal of the vital S·adenosylmethionine supply (Yeo and Wagner,
1994; Wagner et at., 1985). In contrast, when methyltctrahydrofolate concentrations
are low, a sign of excess methionine, the inhibition of glycine N.mcthyltransferase is
removed, pennining the removal of excess SAM (Balaghi et al., 1993).
1,12.3 Coordination of Regulatory Mechanisms
In 1984, Finkelstein and Martin attcmpted 10 investigate the role of each
regulatory mechanism in an assay that would emulate the in vivo situation. To do so
Ihey developed an in vitro system which could simultaneously measurc the reaction
rates of the homocysteine metabolizing enzymes (i.e CBS, BHMT, and methionine
synthase). These measurements provided an accurate picture of metabolic nux since
the system was designed to mimic in vivo conditions. Furthermore, the model allowed
28
for independent variation of enzymes, substrates and related metabolites. The only
discrepancy from the in vivo circumstance is the loss of any specific spatial
relationship or compartmentalization that could occur in the cell. Obviously, their
model was homogenous in nature.
In their first set of experiments, Finkelstein and Martin (1984) evaluated the
effects of dietary methionine on the distribution of homocysteine between competing
enzymes. In hepatic extmets prepared from control rats, methionine synthase, betaine-
homocysteine melhyltransferase and cystathionine j}-synthase accounted for 27, 27,
and 46% of the homocysteine consumed, respectively. Under low-protein conditions
the percentage of homocysteine converted to cystathionine was decreased to 30%,
while a corresponding increase was observed in flux through betaine-homocysteine
methyltransferase. Conversely, under high-protein conditions 90";" of available
homocysteine was catabolized by cystathionine p-synthase.
To further investigate the pathways' adaptation to methionine excess,
Finkelstein and Martin (1986) fed rats diets with varying levels of methionine. The
transsulfuration flux was 12-times higher in the livers taken from rats fed a high-
methionine diet, However, the activity of cystathionine p-synthase was only increased
2-fold. The elevated transsulfuralion flux was inhibited when the concentration of
substrates and regulators, such as methionine, S-adenosylmetllionine, S-
adenosylhomocysteine, and serine were reduced in the as.~ay. In tile low-substrate
conditions there was an increase in remethylation reactions. Finkelstein and Martin
concluded that the large increase in transsulfuration flux, in response to methionine
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excess, was primarily due to increased substrate concentrations rather than changes in
enzyme levels.
1.13 Redox Regulation
Studies with purified mammalian methionine synthase and
cystathionine ~-synthase have revealed that both enzymes are oxidatively sensitive,
leading to the hypothesis that redox regulation of this pathway may have
physiological significance. Methionine synthase was activated under reducing
conditions since more cobalamin was kept in its kinetically active state (Chen el al.,
1995). When cystathionine l3-synthase was incubated with a reducing agent, such as
titanium citrate, enzyme activity decreased by 50% (Taoka et al., 1998). This activity
was nonnalized when the enzyme's heme was reoxidizc<l. Since the product of
transsulfuration, cysteine, is a glutathione precursor redox regulation of its supply is
an attractive mechanism in response to changes in cellular redox potential.
Mosharov et al. (2000) examined metabolite production in HepG2 cells, to
test whether redox changes serve any regulatory role under physiological conditions.
Addition of H202 or t-butyl hydroperoxide increased cystathionine production by 2-
fold. This increase in transsulfuration flux showed a dose-dependent response to both
oxidants. It is important to note that increased flux was not due to alterations in
methionine synthase or cystathionine l3-synthase protein levels. Furthennore, the
concentration of cellular glutathione was increased following t-butyl hydroperoxide
incubation with about half of the glutathione's cysteine being derived from
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homocysteine. This is consistent with early work pcrfonned by Krebs, who showed
that methionine supply was vital in maintaining bepatic cellular glutathione (Nina el
al., 1978). Thus activation of the transsulfuration pathway may provide an adaptive
mechanism to deal with oxidative stress.
J.14lmportance of Homocysleine in Health and Disease
Over 30 years ago, McCully described a child who was homocysteinurie,
secondary to a defect in vitamin BI2 metabolism. The child had aneriallesions that
were similar to those observed in patients with cystathionine ~-syntbase deficiency
(McCully, 1969). He proposed that elevated plasma homocysteine found in
homocysteinuric patients was responsible for the development of vascular disease. Tn
1976, Wilcken and Wilcken presented work supporting the homocysteine theory of
arteriosclerosis. They found evidence of abnonnal methionine metabolism in patients
with unexplained and premature heart disease. These findings have sparked over 2
decades of intense research. In the past decade alone, over 110 studies have
investigated the relationship betwcen vascular disease and total homocysteinc,
defined as the sum of free, oxidized and protein-bound fonns. Nonnal total plasma
concentrations of homocysteine are generally in the range of 5 to 15 JlM.. While a
consensus on precise cut off values has yet to be established, mild
hypcrhomocysteinemia may be defined as concentrations ranging from 15-25 11M,
modcratc between 25-50 11M and severe> 50l1M (Green and Jacobsen, 1995)
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In 1995 a meta-analysis of 27 studies showed that homocysteine was an
independent, graded risk factor for occlusive vascular disease. including coronary,
cerebral, and peripheral vessels. A 5 J.IM increment in total plasma homocysteine was
associated wim an increased risk of coronary heart disease of 60 and 80% for mcn
and women, respectively. It was concluded that the samt: 5 flM increment was
associated with the same risk as a 0.5 mM increase in cholesterol (Boushey et al.,
1995). In a more reccnt study, plasma homocysteine was measured in patients with
confirmed coronary arterial disease with a mean follow-up time of 4.6 years (Nygard
et al., 1997). Aner this time, only 4% of those patients with plasma homocysteine
<9.0 flM died, whereas patients with homocysteine >15 j.lM had a mortality rate of
25%. In the elderly Framingham study population, those in the highest quartile of
plasma homocysteine demonstrated a two-fold increase in cardiovascular disease
mortality compared to those in the lowest (Bostom et al., 1999).
In recent years, the majority of the sulfur amino acid research has been
directed to the precise mechanism whereby homocysteine may cause vascular lesions.
The proposed deleterious effects of homocysteine have ineluded increased platelet
adhesion (Dardik et at., 2000), oxidation of low-density lipoproteins (Voutilainen et
al., 1999), inhibition of nitric oxidc synthase (Upchurch et aI., 1997), interference
with endothelium-dependent vasodialation (Tawakol et aI., 1997), and even
homocysteinylation of proteins (Jakubowski, 1999). To date, consensus on this
subject has not been reached. It is clear that additional studies are required to
pinpoint the mechanism(s) by which homocysteine induces atherosclerosis. It is also
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abundantly clear that homocysteine may internet with a variety of systems, resulting
in different outcomes. Of course, the possibility still exists that homocysteine is a
marker for the actual atherogenic agent.
1.15 Renal Homocysteine metabolism
Increased plasma homocysteine is a common finding in human patients with
end-stage renal disease (ESRD) (Bostam and Lathrop, 1997). Furthermore, these
patients have a severely reduced life expectancy, mainly because of increased risk of
atherolhrombotic vascular disease. The level of plasma homocysteine is inversely
related to the glomerular filtration ratc (GFR) (Arnadottir et al., 1996). This
dependency is observed in normal subjects, in ESRD patients, and even extends to
hyperfiltering diabetic patients (Wollcscn et al., 1999). Ofcourse, a change in GFR is
only one determinant of plasma homocysteine in renal disease. As one might expect,
folate and vitamin B6 status arc major concerns for ESRD patients, due to increased
loss following dialysis (Deseombes et al., 1993). However, superphysiologieal doses
of B-vitamins, while normalizing vitamin status, only partially reduce plasma
homocysteine and many patients still have levels greater than normal subjects
(Boslom et al., 1996). Indeed, the renal handling of homocysteine is an important
topic and much work has bcen carried out on how the human and rat kidneys
mctabolize plasma homocysteine.
As mentioned earlier, various forms of homocysteine are present in plasma. In
humans, about 80% of homocysteine is protein bound with the remaining 20%
JJ
consisting of mixed disulfides, homocystine and reduced homocysteine (Green and
Jacobsen, 1995; van Guldener and Robinson, 2000). In contmst, rat plasma consislS
only of 20-30% protein-bound homocysteine (House et a1., 1998). The fmction of
free homocysteine is important since protein-bound homocysteine is not available for
filtration by the glomerulus. Homocysteine filtered by the glomerulus is almost
completely reabsorbed by tubular cells with only I% of the filtered load being
excreted (House er al., 1998). Studies perfonncd in vivo in our labomtory showed that
rat kidneys have substantial capacity for reabsorbing homocysteine. In fact, when
plasma homocysteine was elevated 6~fold, either by homocysteine infusion or
exposure to nitrous oxide, there was a proportional increase in filtered homocysteine;
however the percentage of total homocysteine excreted in the urine was unchanged
(House et al., 1998). Taken together with human data, impainnent of homocysteine
excretion cannot account for hyperhomocysteinemia in end-stage renal disease.
Our laboratory has shown, in rats, that approximately 20% of the arterial
homocysteine was removed on passage through the kidney (House et al., 1998). Since
the excretion of homocysteine is negligible in healthy mts, the kidney appears to be a
major site for removal and metabolism of plasma homocysteine. Furthermore, when
isolated renal cortical tubules were incubated with homocysteine, only 2% was
converted to methionine (House el af., 1997). The production of cystathionine, and
subsequently cysteine, accounted for the greater pan of the homocysteine
metabolized. In addition, the (lux through the transsulfumtion pathway, and thus the
disappearance of homocysteine, was enhanced by serine.
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In contrast to rats, nonnal fasted humans have no significant arteriovenous
difference in homocysteine concentration across the kidney (van Guldencr el at.,
1998). The very large free fraction of homocysteine in rat plasma, as compared to
humans, may explain why rats have increased homocysteine uptake and subsequent
metabolism. The renal complement of enzymes is another striking difference between
humans and rats. While rat kidney has methionine synthase. most of the
homocysteine removal occurs via the transsulfuration pathway (House et al., 1997).
Humans, however, have significant levels ofbelaine:homocysteine methyltransferase
(Mckeever et at., 1991). Even more important is the low renal activity of
cystathionine ~-synthase, although the human kidney does express CBS mRNA
(Stunnan el al., 1970; Quere et at., 1999). It is apparent that, while rat kidneys
metabolize homocysteine via the transsulfuration pathway, humans remove
homocysteine, if it happens at all, via remethylation. It is cunous that human kidneys
do contain cystathionine y.lyase suggesting that this enzyme has a metabolic role
independent of the synthase, such as in cysteine metabolism (Stunnan et al., 1970).
Of course cystathionine y-lyase may metabolize cystathionine imported from the
plasma. Although it is clear that hyperhomocysteinemia occurs in end-stage renal
disease, indisputable evidence for the removal of homocysteine by human kidneys
has yet to be documented.
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1.16 Thyroid hormone in humans
Hypothyroid patients have an increased risk for cardiovascular discases
(Vanhaelst el al., 1967). Autopsy studies have shown that the atherosclerotic process
is twice as common in hypothyroid patients compared with nonnal subjects, and is
decreased in hyperthyroidism (Steinberg, 1968; Grytting and Salvesen, 1957). The
increase in cardiovascular disease in hypothyroidism has been linked to lipid
abnonnalities and hypertension, such as increased concentration of plasma low-
density lipoprotcin cholesterol and elevated diastolic blood pressure (Williams and
Braunwald, 1984; Streeten el al., 1988). However, these factors do not explain
atherogenesis in all hypothyroid patients, suggesting that another mechanism may be
involved.
There are now consistent reports that thyroid status can influence plasma
homocysteine levels in humans. Nedrebo et al. (1998) observed that total plasma
homocysteine concentrations were elevated in hypothyroid patients versus controls,
while hyperthyroid patients tend to have lower plasma homocysteine levels.
Furthennore, Hussein et al. (1999) detennined that restoration of euthyroidism, by L-
thyroxine treatment, normalized plasma homocysteine; however the mechanism by
which thyroxine elicits its effects is currently under debate. Altered vitamin status in
hypothyroid patients is one possibility since retention of liver folate has been
observed in the hypothyroid rat (Stokstad et af., 1980). Patients with hyperthyroidism
tend to have higher plasma folate levels than do hypothyroid patients (Nedrebo et af.,
1998, Diekman et al., 2001). Functional riboflavin deficiency has also been reported
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in the hypothyroid rat. with decreased levels of FAD and FMN observed in thc liver
(Rivlin, 1970). This deficiency bas been associated with decreased activities of many
riboflavin-dependent enzymes. It is not known, however, if these defects are related
to homocysteine metabolism. In a longitudinal smdy, Nedrebo et al. (2001) reported
that folate and cobalamin status could not explain the change in plasma homocysteine
following thyroxine treatment. Furthennore, they observed parallel changes in serum
creatinine concentrations, suggesting that changes in renal function rather than
vitamin status may account for the altered plasma homocysteine levels. Both animal
and human studies have demonstrated that hypothyroid patients tend to have low
glomerular filtration rates, while hyperthyroidism is associated with an elevated GFR
(Capasso el al., 1999; Kreisman et al., 1999). Although evidence suggests that altered
renal homocysteine handling may be responsible for the changes in plasma
homocysteine observed in hypothyroidism, it is still plausible that altered metabolism
in other tissues may contribute 10 tbis change.
1.17 Diabetes Mellitus
Vascular disease is the scourge of any diabetic patient. Diabetics are two, two
to ten, and five to ten times more likely than healthy individuals to have strokes.
myocardial infarctions, and peripheral vascular problems, respectively (Ellenberg and
Rifkin, 1990). The survival rate following a stroke or myocardial infarction is also
much lower in diabetics compared to non-diabetics (Smith et al., 1984; Oppenbeimer
el al., 1985). Many factors contribute to accelerated atherosclerosis in diabetics
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including genetic pre-disposition and diet. In addition, the amplifying role of other
risk factors, such as high blood pressure, smoking, and high plasma cholesterol has
been documented (Ellenberg and Rifkin, 1990). As homocysteine is a recognized risk
factor for vascular disease, much attention has been given to the possible relationship
between diabetes mellitus and plasma homocysteine.
in 1991, Hultberg et al. were the first to report. altered homocysteine
metabolism in diabetic patients. They observed that Type I diabetics, who showed
signs of renal damage, had elevated plasma homocysteine compared to diabetic
patients without renal complications. In their follow-up study, Hultberg et at. (1997)
reported that Type I adult patients, who had the longest duration of disease and
poorest metabolic control, were the most prone to increased levels of plasma
homocysteine. Similar relationships were not observed in adolescent diabetic patients.
However, the duration of disease in those patients was far shorter than in the adult
study. Hyperhomocysteinemia is not nonnally observed in diabetic patients until the
onset of renal disease or microalbuminuna (Pavia el al., 2001; Chiarelli et al., 2000).
Furthennore, Robillon et al. (1994) observed that the Type I diabetic patients,
without cardiovascular disease or renal impainnent, had decreased plasma
homocysteine compared to healthy individuals. This result was confinned in a larger
study by Cronin Cf al. (1998). These studies could not provide an explanation for the
subnonnal levels of plasma homocysteine; however the possible regulation of
homocysteine metabolism by insulin could afford an explanation.
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1.18 Objectives oflnvestigatloD
Clinical studies on diabetics and hypothyroid patients have suggested that
insulin and thyroid honnonc may havc a role in regulating homocysteine metabolism.
To date, no studies have been undertaken to investigate possible mechanism(s), if any
exist, by whieh insulin and thyroid honnonc regulate homocysteine metabolism. We
therefore complctcd a series of studies with the following questions in mind:
I. Does the streptozotocin-diabetic rat mimic human type I diabetes mcllitus
with rcspL'Ct to plasma homocysteine?
2. What role does insulin play in regulating homocysteinc mctabolism? What
is/are the mechanism{s) of action?
3. Does hyperglucagonemia, a common charactcristic of diabetes mellitus, have
a role in regulating homocysteine metabolism?
4. Does the hypothyroid rat mimie human hypothyroidism with respect to
plasma homocysteine? What role, if any, docs thyroid honnonc play in
regulating homocysteine metabolism.
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Chapter 2:Methods and Materials
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2.1 Chemicals
All chemicals were of the highest quality available and were purchased from
Sigma (Oakville, ON, Canada), except where noted in the text.
2.2 Animal treatment
Mate Sprague·Oawlcy rats (supplied by the University's breeding colony)
weighing between 200·300 grams wcre fed ad libitum either an AIN 93 growth diet
or laboratory chow, and had free access to water. The rats were expose<! to a 12-hour
light: l2-hour dark cycle beginning with lights on at 8 am. All studies were conducted
irrunediately following termination of the dark cycle. All procedures were approved
by Memorial University's Institutional Animal Care Committee and are in accordance
with the principles and guidelines of the Canadian Council on Animal Care.
2.3 Enzyme assays
J(jdneys and liver were rapidly removed from an anaesthetized rat (65 mglkg
sodium pentobarbital, i.p.) and placed in icc-cold 50 mM potassium phosphate butTer,
pH 6.9. Tissues were diluted (5: I voVwt) with the phosphate butTer, then
homogenized with a Polytron homogenizer (Brinkman Instruments, Toronto, Canada)
for 20 seconds at 50% output. The homogenales were centrifuged at 18,OOOg at 4°C
for 30 minutes and the supernatant retained. All enzyme assays were carried out on
this 18,ooog (postmilochondrial) supernatant. Assays were shown to be linear with
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respect to time and protein before usc in any experiment. The conditions used for
each enzyme assay arc given in Table 2-1.
2.3.1 Methionine adenosyltransferase
Methionine adenosyltransferase activity was dctcnIlined using the assay
developed by Mudd et al. (1965). The incubation mixture consisted of 133 filM Tris-
HCI (pH 7.6), 177 mM KCI, 266 mM MgC12, 16 mM ATP, 3.5 mM glutathione, 0.26
filM S-adenosylmethionine, 0.131 mM J4CH3-methionine (ISO x 103 dpm), and
cytosol. The reaction was started with the addition of cytosol and incubated at 31'C
for 30 minutes in a final volume of 0045 m!. The reaction was stopped by the addition
of ice-cold walerto a final volume of 11.5 m!. A 5 ml-aliquot of the resulting solution
was added to a column (0.9 x 2.0 em) of Dowex 50-x4 (NH/). The column was
washed with 10 ml of water and the radioactive S-adenosylmcthionine was eluted
with 10 ml 3 N NaOH. A sample was taken and radioactivity measured. The value
obtained from incubation with heat-inactivated enzyme was used as a blank. Linearity
with time and protein was demonstrated previously in our laboratory (Stead,
unpublished data).
2.3.2 Glycine N-methyltransferase
This assay is a modified version of Wagner's method (Cook and Wagner,
1984). The reaction mixture (I ml) consisted of 0.2 mM eH-CH3]-S-
adenosylmcthionine (1.0 mCi/mmol), 10 mM Tris-HCI buffer (pH 9.0), 0.5 mM
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Table 2·1: Summary of enzyme auay conditions of time and protein for both
liver and kidney samples.
Liver Kidney
Time Protein Time Protein
(min) (mg) (min) (mg)
Methionine Adenosyltransferase 30 0.75 "d "d
Glycine N-methyltransferase 20 0.15 "d "d
Cystathionine ~-synthase 40 0.3 30 0.4
Cystathionine y-Iyase 10 I.S 10
Methionine Synthase 30 1.0 30 0.75
Betaine:homocysteine methyltransferase 30 0.3 "d "d
Methylenetetrahydrofolate reductase 15 0.15 15 0.1
Assay conditions are given in the text. All assays were carried out al 37°C, except that
for glycine N-methyltransferase which was at 25°C. nd- activity not detennincd.
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dithiothreitol (DIT), 0.2 mM glycine and cytosol. Following the addition of glycine,
to start the reaction, samples were incubated at 25°C for 15 mins at which point the
reaction was stopped by the addition of 50 lJ.I of ice-cold 10% w/v TCA. 250 lJ.I of an
acid-washed charcoal suspension (38 mg/ml, in 0.1 M acetic acid) was added to bind
all umcacted S-adenosylmcthionine. Tbe samples were incubatcd on ice for IS mins
and then spun for 10 mins at 3200g in a Brinkman benchtop centrifuge. 200 lJ.I of the
supernatant was added to 10 ml of scintillation cocktail and the radioactivity
detennined. This assay was shown to be linear between 50-250 lJ.g of eytosolic
protein and up to 30 mins of incubation time (Williams, 1998).
2.3.3 Cystathionine ~-Synthasc
Cystathionine ~-synthase was measured by the method of Miller et al. (1994).
Incubation mixtures (120 lJ.1) consisted of 16.6 mM serine, 0.83 roM EDTA, 0.42 mM
pyridoxal 5-phosphate, 33 mM d,l-homocysteine and 0.42 mM propargylglycine in 1
M Tris buffer, pH 8.4. The reaction was started with tbe addition of cytosol,
incubated at 37"C, and stopped with tbe addition of 100 lJ.1 of 10% SSA. Each sample
was then centrifuged at 14,ooog for 5 mins. Cystathionine concentrations in the
supernatants, following neutralization, were detennined by HPLC. Linearity with
respect to time and protein are shown for the liver in Figure 2.1 and the kidney in
Figure 2.2.
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Figure 2.1: Dependence of cystathionine production by hepatic cystathionine p.
synthase on time and protein concentration. Linearity with respect to protein was
determined using a 30 minute time period. The time curve was obtained using 0.3 mg
of protein. Typical graph is shown.
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Figure 2.2: Dependence or cystathionine production by renal cystathionine fI-
synthase on time and protein concentration. Protein linearity was evaluated using a
30 minute time period. The lime curve was obtained using 0.3 mg of protein. Typical
graphs are shown.
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2.3.3.1 Determination of cystathionine and metbionlne by HPLC
Concentrations of methionine and cystathionine were detennined using a
Waters automated HPLC system which includes the following equipment a Model
600E System Controller, a Model 712 WISP sample injector, a Model 420
Fluorescence Detector, and a 743 Data Module. Following derivatization with 0-
phthalaldehyde (OPA), the samples were injected into a Hypcrsil ODS-CI8 column
(4.6 x 150 nun). The chromatographic conditions were described previously by Jones
and Gillingham (1983). Buffer A contained 0.05 M sodium acetate and 0.05 sodium
phosphate (pH 7.5), which was mixed with methanol and tetrahydrofuran in a ratio of
96:2:2, respectively. Buffer B contained methanol and water in a ratio of 65:35. The
amino acids were resolved using a 47-minute linear gradient from 100% buffer A to
100% buffer B at a flow rate of 1.5 mUntin. The fluorescence intensities were
measured with excitation at 334 nm and emission at 425 run. The level of methionine
and cystathionine was calculated by comparing the area under the peak with that of
AEC (aminoethyl-cysteine), an internal standard.
2.3.4 Cystathionine y-Lyase
Cystathionine y-Iyase activity was measured using the method of Stipanuk
(1979). Cytosolic protein was added to a 2 ml cocktail consisting of 100 mM
potassium phosphate (pH 7.5), 4.0 mM cystathionine, 0.125 mM pyridoxal 5-
phosphate, 0.32 mM NADH, and 1.5 units of lactate dehydrogenase (LDH). In this
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assay, a-ketobutynue serves as a substrate for LDH. Therefore, NADH oxidation is
measure of a-ketobutyrate production by cystathionine y.lyase. The decrease in
optical density at 340 nm was monitored speetrophotometrically at 37°C. All
measurements were taken from the linear portion of the graph. Blank reactions were
perfonned using a cystathionine-free cocktail. Linearity with respect to protein is
shown for the liver in Figure 2.3 and the kidney in Figure 2.4.
2.3.5 MethyJenetctrabydrofolate reductase
Mcthylenetetrabydrofolate reductase activity was detennined radiochemically
by the method of Engbcrscn et al. (1995). Thc reaction cocktail (600 1J.1) consisted of
0.18 M potassium phosphate buffer (pH 6.8), 1.15 mM EDTA, 11.5 mM ascorbic
acid, 54 IJ.M FAD, 20 IJ.M [14C.CH)]melhyltctrahydrofolate (0.20 IJ.Ci), 3.5 mM
menadione, and cytosolic protein (100 IJ.I). A zero-time point was used as a blank for
this assay. The reactions were started with the addition of menadione and incubated in
the dark at 3~C, and stopped by the addition of 10 IJ.I of 1.0 M formaldehyde, 50
IJ.mol dimedone in 200 IJ.I ethanol:water (1:1), and 100 1J.13.0 M potassium acetate,
pH 4.5. The test tubes were heated at 95°C for [5 mins then cooled in an ice-bath for
10 mins. 3 mls of toluene were added to the tubes, mixed vigorously, centrifuged at
low speed tor 5 mins, and then 2.0 ml of the toluene phase was taken for
measurement of radioactivity. Linearity with time and protein is presented for the
liver in Figure 2.5 and in the kidney in Figure 2.6.
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Figure 2.3: Dependence of hepatic cystathionine y-Iyase on protein
concentration. The activity was evaluated over a 10 minute period. A typical graph
is shown.
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Figure 2.4: Dependence of renal cystathionine "'(.Iyase on protein concentration.
The activity was evaluated over a 10 minute period. A typical graph is shown.
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Figure 2.5: Linearit)' with protein concentratiou and time for hepatic
methylenetetrahydrofolate reductase activity. The protein curve was obtained
using a 15 minute time period. The linearity with respect to time was determined
using 0.15 mg of protein. Typical graphs arc shown.
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Figure 2.6: Linearity with protein concentration and lime for renal
mcthylenctctrahydrofolale rcduehasc acth'lty. The protein curve was obtained
using a 15 minute time period. The linearity with respect to time was detennined
using 0.10 mg of protein. Typical graphs are ShO\'ffl.
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2.3.6 Methionine synthase
Methionine synthase was measured using the method described by Koblin et
a!. (1981). The reaction mixture consisted of 87.5 mM potassium phosphate buITer
(pH 7.5). 7.5 mM homocysteine, 29 roM dithiothreitol, 0.25 mM S-
adenosylmethionine, 10 liM cyanocobalamin, 7 mM p-mcrcaptoethanol, 0.5 mM [5~
14C]methyltctrnhydrofolate (0.25 IlCi), and eytosolic protein. The reaction was started
by addition of cytosol and was then gassed with nitrogen, capped, and incubated in
the dark at 3'f'C. The reactions were stopped with 0.5 ml of ice-cold water and
immediately added to the top ofa Biorad AGI-X8 (200-400 mesh) column (Cll The
column was washed 3 times with 0.5 ml water. The resulting effluent was added to 10
ml Seintiverse and the radioactivity measured. Linearity with respect to time and
protein are shown for the liver (Figure 2.7) and kidney (Figure 2.8).
2.3.7 Betaine:homoeysteine methyltransferase
Belaine:homocystcine mcthyltransferasc activity was mcasured using a
method developed by Wang et 01. (1991) with modifications. The reaction mixture
(200 ,...1) contained 75 mM sodium phosphate (pH 7.4), 3.25 mM betaine, 10 mM d,l-
homocystcine, and cytosol. Samples were incubated at 3~C and stopped by the
addition of I(){) ,...1 of 10% SSA. The samples were kept on ice for 10 mins, then
centrifuged for 5 mins at 14,000 rpm. The supernatant was retaincd and methionine
measured by HPLC, as described in section 2.3.3.1. Linearity with respect to time and
protein are shown in Figure 2.9.
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Figure 2.7: Dependence or 14C-methionine production by hepatic methionine
synthase on time and protein concentration_ The protein curvc was obtained using
a 30 minute incubation period. The time curve was detennined using 1.0 mg of
protein. Typical graphs are shown.
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Figure 2.8: Dependence of 14C-methioninc production by renal methionine
synthase on time and protein concentration. The protein curve was detennined
using a 30 minute incubation period. The time curve was obtained using 0.75 mg of
protein. Typical graphs are shown.
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Figure 2.9: Dependence of methionine production by bctainc:homocysteine
methyltransferase on protein and time. The protein curve was obtained using a 30
minute incubation period. Linearity with respect to time was demonstl1lted using 0.3
mg of protein. Typical curves are shown.
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2.4 Plasma hormones, glucose and creatinine
Blood samples were collected from the abdominal aorta of anaesthetized rals
(65 mglkg sodium pentobarbital, i.p.). Heparinized tubes containing the blood
samples were placed on ice until plasma was separated by centrifugation in a clinical
centrifuge (15 mins, 3700 x g). The plasma was then frozcn (.20°C) for later use.
Plasma levels of total TJ and free T4 were measured hy the St. John's General
Hospital clinical laboratory (auloDELFIA kit, Pharmacia, Baic d'Urfe, Que.). insulin
and glucagon levels were measure by Linco Researeh Inc. (St. Charles, MO) using rat
insulin and glucagon, respectively, as standards. Glucose (Bergmeyer el aL, 1981)
and creatinine (Sigma kit) concentrations were determined using standard methods.
2.5 Total homocysteine measurements
Total homocysteine concentrations were determined by the method of Vester
and Rasmussen (1991). 20 III of 10% tri-n-butyl-phosphine in dimcthylformamide
was added to 150 ul of sample (plasma liver or hepatocytes). Following a 30 minute
(4°C) reduction period, the samples were dcproteinized by the addition of 125 III of
0.6 M perchloric acid. 50 III of 0.2 mM 8-aminonaphtalene-I,3,6-trisulfonic acid was
added and the tubes centrifuged at 14,000g (Brinkman Instruments, Rexdale, ON,
Canada) for 5 min (40 q. Then, 100 III of the supernatant was added to an Eppendorf
tube containing 200 III of 2 M potassium borate, pH 10.5, containing 5 mM EDTA
and 100 III of ammonium 7-fluorobenzo-2-oxo-1 ,3·diazo!c-4.sulphonate solution (1.0
gil in 2 M potassium borate, pH 9.5). Following an incubation period (60°C, 60 min),
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the samples were cooled in an ice bath (IS mins), at which point 20 ~I of the
derivatized sample was analysed by HPLC.
2.5. t HPLC apparatus and conditions
A Man-Tech Shimadzu system (Pump GT-104, SCL-IOA Controller, SIL-
lOA Auto Injector, LC·IOAD Liquid Chromatograph, RF-535 Fluorescence Monitor)
equipped with a Phase Separations Hypersil CIS-ODS analytical colwnn (4.6 x 150
mm) was used to measure homocysteine. The fluorescence intensities were measured
with excitation at 385 nm and emission at 515 run. The detection signal was recorded
and peaks quantified using a Man-Tcch Shimadzu CRSOI Chromatopac intcgralOr.
The chromatographic conditions were modified from those used by VeslOr
and Rasmussen (Vestor and Rasmussen, 1991). The butTers consisted of 0.1 M
acetate (pH 4.0) mixed with 20 or 200 mill methanol for solution A and B,
respectively. These buffers were filtered through a OA5 flm Millipore filter before
use. A linear gradient was run from butTer A to buffer B over 12.5 minutes, then 2.5
minutes buffer B, a three minute linear gradient back to butTer A, and finally 2
minutes with buffer A, at a flow rate of 1.00 mVmin.
2.6 Amino acid analysis
Plasma and liver amino acids were detennined by the Department of
Biochemistry's amino acid facility. Plasma or freeze-clamped liver were first
deproleinized with 10% sulfosalicylic acid. FoJlowing centrifugation, the resulting
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supernatant was adjusted to pH 2.2 with lithium citmte buffer. The samples were then
analyzed on a Beckman 121 MB Amino Acid Analyser using Benson D-X, 0.25
Calion Xchange Resin and a single column, three buffer lithium method as per
Beckman l21MB-TB-017 application notes. Results were quantitated using a Hewlett
Packard Computing Integrator Modc13395A.
2.6.1 Calculation of intracellular hepatic amino acid concentrations
Intracellular hepatic amino acid concentrations were calculated and are
reported in Chapler 5 using published data from our labomtory on hepatic cellular
spaces (Qian and Brosnan, 1996). The measured hepalie concentration for an amino
acid is the sum of the amino acid in the intracellular fluid (leF) and the amino acid in
the extracellular fluid (ECF). The following equation was used to determine the
hepatic intracellular concentration of an amino acid.
TOIaIliver AA (nmollg}-{Plasma AA(nmollml)*ECf (mUg liver)+ Intracellular AA(nmollml}"ICF(mUg liver)]
Intracellular water was previously found to be 0.45 mUg liver while the extracellular
water was 0.25 mUg liver. These values were obtained in control rats. II should be
noted that glucagon, in vitro, has been shown to decrease hepatocyte volume by 5-
10%, we did not take this inlo account (vom Dahlel al., 1991).
2.7 S-Adenosylmethionine and S-adenosylhomocysteine determination
S-Adenosylmctbionine and S·adenosylhomocysteine were measured in the
liver using the method of Wagner with minor modifications (personal
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communication). Freeze-clamped liver was quickly added to 5 volumes of 8% ice-
cold trichloroacetic acid. Samples were homogt..'Tlized with a Polytron for 10 seconds
at 20% output and were placed on ice for 10 minutes. The samples were thcn
centrifuged for to minutes at 13,000g. The supernatant was retained and analysed by
HPLC using a VYDAC CI8 column (#2187P54) Iltat was equilibrated with 96% 50
mM NaH2P04. to mM heplane sulfonic acid (adjusted to pH 3.2 with concentrated
sulfuric acid) and 4% acetonitrile. A IS minute gradient from 4% to 20% acetonitrile
was used to separate SAM and SAH. Peaks were monitored by UV detection at 258
run and quantified using a 3390A Hewlett Packard Integrator. The concentration of
SAM and SAH was calculated using a standard curve shown in Figure 2.10.
2.8 Isolation or Primary Hcpatoeytcs
Primary rat hepatocytes werc isolated via the method of Berry et at. (1991).
An anaesthetised rat was injected with 100 j.LI heparin (1000 units/ml) through the
femoral vein. A cannula was then inserted into the portal vein and perfusion
commenced immediately with 500 ml calcium-free Krebs·Hense1cit medium (144
mM Na·, 6 mM K'", 1.2 mM M~"', 126 mM cr, 1.2 mM H2 P04', 1.2 mM sol', 25
mM HC03) containing 2 mM EGTA, 20 mM glucose, 2.1 mM lactate, 0.3 mM
pyruvatc (pH 7.4). The flow ratc was 40 ml/minute and the medium was gassed with
19:1 02/C02 for 20 minutes before usc. Fonowing a 12 minute flow through period,
the medium was switched to 500 ml Krebs-Hcnsc1eit medium containing 1.3 mM
Ca2+, 20 mM glucose, 2.1 mM lactate, and 0.3 mM pyruvatc (also gassed for 20 min
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Figure 2.10: Standard curve of S-adenosylmethionine and S-
adenosylhomocystcinc. The graph illustrates that both S-adenosylmethioninc (y =
97199X - 1925) and S-adcnosylhomocystcine (y '" 174900X - 426) were linear
between and 0.5 nanomoles. A typical graph is shown.
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before use). A cannula was inserted through the right atrium and into the inferior vena
cava. Krebs-Hcnseleit medium supplemented with 0.25 % eSA and collagenase (50
mgllOO mL) was then recirculated through the liver. To start the flow through the
liver the inferior vena cava was cut below the kidney. The recirculation of perfusate
continued until the liver became soft (15-20 minutes), at which point the liver was
transfcrred to a petri dish containing collagenase medium and massaged gently to
liberate cclls. The resulting suspension was incubated at 3flc for 10 minutes in a
shaking water bath uoder constant gassing (19:1 OlIC02). Following filtration
through a cheesecloth, the cells were centrifuged at 600 rpm for 2 minutes and the
cells resuspended in Krebs-Henseleit medium containing calcium, and the process
repeated. A final wash with Krebs-Henseleit medium containing 2.5% eSA was
completed, and the cell pellet was resuspended in this mcdium. Hepatocytes were
quantified by drying 3.0 ml of resuspended cells and 3.0 ml of 2.5% BSA Krebs-
Henseleit medium in tared vessels at 50°C for 24 hours. The difference in the weights
represented the dry weight of the cells. Cell viability was detennined by 0.1% trypan
blueexelusion.
2.8.1 Homocysteine export from isolated hepatocytes
Hepatocytes were preineubated for 20 minutes at 4-6 mg dry weight of
eells/ml (1m! final volume) in Krebs-Hensleit medium containing 1.25 % (w/v) BSA.
Following preincubation, 1 mM methionine with or without 1 ruM serine was added
and cells were incubated for another 30 minutes. Cells were gassed with 19:1 Oz/C02
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at the beginning of preincubation and at the addition of substrates. At the end of the
incubation, the contents of the flasks were irrunediately centrifuged at 14,000g for 30
seconds to sediment the cells. The supernatant, containing any exported
homocysteine, was then frozen at _20°C umil analysis (Stead et al., 2000).
2.8.2 14COl production by Isolated hepatocytes
The second step of the transsulfuration pathway invol\'es the production of a-
ketobutyrate. Incubation with [1-14C]methionine will give rise to [I_14eja_
ketobutyrate. {1-14eja-Ketobutyratc is a substrate for pyruvate dehydrogenase, which
will release 14C02. Label in unmetabolised [lYeja-ketobutyrate can be released
with hydrogen peroxide. The sum of these two numbers can be used as a measure of
flux through the tnmssulfuration pathway.
Hepatocytes were incubated with I mM L-[1.14ejmethionine (American
Radiolabcled ChemicaJs, Inc., St. Louis, MO) in the presence and absence of
propargylglycine (an inhibitor of cystathionine y-lyase) and a-cyannocinimate (an
inhibitor of the mitochondrial a-ketoacid transporter). Following the addition of
methionine, flasks were incubated for 30 minutes, after which they were equipped
with rubber septa with suspended plastic centre-wells containing NCS tissue
solubilizer. lncubations were tenninated with 0.3 ml 30% (wtlvol) perchloric acid,
added through the septa with a syringe, and 14C02 was collected for I hour. The
centre-wells were added to scintillation vials containing Omnifluor scintillation fluid.
A new centre-well was then added to each flask and 0.3 ml 30% (wtlvol) hydrogen
7J
peroxide was added through the septum with a syringe. 14C02 was collected for I
hour and measured as deseribed above.
2.8.3 Methionine transport into isolated hepatocytes
Methionine transport into isolated hepatocytes was measured as described by
Salter et al (1986). Cells were pre-incubated for 20 minutes and then 1_14C_
methionine was added at a final concentration orO.5 mM (400 dpmlnmole). At 5, 35,
65, 95, and 125 scconds following the addition of methionine, 1 ml aliquots were
transfcrrcd to 1.5 ml microcentrifuge tubcs containing 0.25 ml of silicone oil mixture
(2:1 (v/v) Dow Corning 550 silicone oil and dinonyl phthalate) layered on top of 0.1
m16% (v/v) perchloric acid. The tubes were centrifuged at 14,ooog for 15 seconds to
sequester cells through the silicone oil and into thc acid layer, leaving the
extracellular component on top of the oil. Following centrifugation, thc tubes were
frozen in liquid nitrogen and thcn werc cui through at thc bottom of thc silicone oil
layer. The bottom layer, containing the intracellular 14C_methionine, was placed in a
scintillation vial containing 10 ml Omnifluor scintillation cocktail and radioactivity
detennined in a scintillation counter. The volume of extracellular space that was
sequcstered through the silicone oil was delennined by measuring the bottom layer
following parallel cell incubations with carboxyIYC-inulin. This value was used to
correct rates of methionine transport. Methionine transport rates wcrc detennincd by
subtracting 5 sccond rates, representing primarily amino acids binding to membranes,
from the values obtained at subsequent time points.
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2.9lsolatloo of total RNA and Northern blot analysis
Total RNA was isolated from rat livers by tbe acid guanidinium thiocyanate-
phenol.chlorofonn method as described by Chomczynski and Sacchi (1987). 15 ~g of
total RNA were separated on a 1% agarose gel containing fonnaJdehyde and
transferred to a Hybond·Nylon membrane (Amersham Life Sciences). cONAs for
cystathionine p-synthasc, cystathionine y-lyasc, and p.actin (Clonlech) were labeled
with [ct_32P]dCTP using a random-labeling kit (Ambion). The probes (specific
activity _109 dpmJug) were allowed to hybridize to the membrane for 16 hours at
42°C in Northern Max™ ultrahybridization buffer (Ambion). Autoradiography was
by exposure (8 hours to 3 days) of the blot to Kodak XAR film. The results were
analyzed by densitometry of the bands on autoradiograms. The levels of cystathionine
p-synthase and cystathionine y-tyase mRNA were nonnaliscd to the amount of RNA
applied, using the housekeeping gene p-actin, by setting the ratio of cystathionine p-
synthase mRNA to that ofp-actin in the control animals to I.
2.10 Cell Culture
H411E rat hepatoma cells (American Tissue Culture Collection, Rockville,
MO) were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing I(}%
v/v Fetal Bovine Scrum (FBS), \00 units/ml penicillin and 100 Ilg/ml of streptomycin
(Canadian Life Technologies, Burlington, ON) under 5% C02/95% O2 in a
humidified incubator at 37°C until they reached near confluency (70%). Cells were
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made quiescent by an overnight incubation with medium containing 0.5% FBS. Prior
to the addition of honnones (triamcinolone, insulin, glucagon), cells wcre washed
once with OPBS, then the fresh medium containing 0.5% FBS was replaced. Thc
plates were incubated at 37°C for various time periods ranging from 0 to 24 hours.
Cell viability was monitored by trypan blue exclusion.
2.10.1 Reverse transcriptasciPolymerase Chain Reaction (RT·PCR)
2 1!8 of total RNA were rcverse transcribed using a one step reverse
transcription kit (Qiagen) and amplified for 30 cycles. The upstream primer
corresponding to 41 to 53 base pairs (5'-GCCTTCAGGACATCCAGTGT-3') and a
down stream primer (5'-TCTIlCCGGGTCTGCTCACGGGC-3') corresponding to
1661-1684 base pairs of the type 3 rat CBS cDNA (gift from Dr. J. Kraus) were used
to amplify 1644 base pair PCR fragment. A 768 bp fragment of the rat l3-actin was
co-amplified using primers obtained from Clonctech Laboratories (palo Alto, CAl.
peR products were separated on a 0.8% agarose gel and cthidium bromide-stained
bands were visualized by UV illumination. Before transfer to a membrane (S and S
nytran SuPer charge<ll nylon) the gel was immersed in 0.25 N HCI for 30 min,
incubated in denaturing solution (1.5M NaC!, 0.5M NaOH) for 30 mins, rinsed with
distilled water, soaked in neutralization buffer (0.5 M Tris-HCI, pH 7.0, 1.5 M NaCI),
and washed in lOxSSC. The transferred DNA was immobilized by UV crosslinking
(Hoefer UVC 500 UV crosslinker). The blots were simultaneously probed with 32p
labelled CBS eDNA, and radiolabel1cd Il·actin cDNA probe (Clonetcch Laboratories,
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Palo Alto, CAl. Autoradiograpny was by exposure of tne blot to Kodak XAR or
Biomax fi[m.
2.10.2 Western blot
At the end of the incubation witb honnones, the medium was aspirated and
cells were washed once with PBS. Cells wcrc then lysed in sodium dodceyl sulphate
(8DS) sample buffer (62.5 mM Tris-HCI, 2% SOS, 10% glycerol, 50mM
dithiothrcitol and 0.1 % bromophenol blue), scraped off the plate and sonicated for 10-
15 seconds to shear DNA and reduce viscosity. Protein concentration of the cell
Iysates was detennined by SCA method (Pierce Chemical Co., Rockford, IL) using
bovine serum albumin as a standard. Following a 5 minute (95-100°C) incubation
period, protein bands were separated on a 12% 80S-PAGE and transferred to 0.211
pore size nitrocellulose membranes (BioR3d, Hercules, CAl. Membranes were
washed with blocking buffer (5% non fat dry milk in TSS containing 0.1% Tween-
20), incubated with rabbit anti-CBS polyc1onal antibody (I :5000 dilution in blocking
buffer), rinsed, and incubated with anti-rabbit IgG conjugated to horsc-radish
peroxidase (1:2000 dilution in blocking buffer). The amount of CBS protcin was
determined by a chemiluminescent detection system containing hydrogen peroxide
and LumiGLO reagent, followed by exposure of membranes to Kodak Biomax ML
film.
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2.11 Renal Homocysteine Flux
Studies were carried out to measure homocysteine removal by the kidneys.
Previous work in our lab has shown that the kidneys arc very important tissues in the
removal of plasma homocysteine (House ct at., 1998). Two measurements are
required to quantify renal homocysteine flux: an arterial-venous (A-V) difference for
homocysteine and renal plasma flow. The A-V difference across the kidney for
homocysteine gives only a qualitative picture and therefore requires quantification.
When the A-V difference is multiplied by the plasma flow one has a quantitative
measure of homocysteine uptake.
The methodology used was similar to that previously employed in Lowry et
aJ. (1987) and more recently by House el al. (1998). Briefly, an anaesthetised rat was
placed on a heating pad and the trachea was cannulated with a small piece (2.5 em
long x 2.5 mm ID) of polyethylene tubing. The right jugular vein was then
catheterised with PE-50 tubing for the infusion of inulin. A priming dose of 1.75 flCi
of (carboxyl-14C]inulin (New England Nuclear, Lachine, Quebec) in 0.8 ml of 10%
mannitol-Q,45% Nael was given through the saphenous vein and followed by the
continuous infusion of the same solution at a rate of 0.037 mVmin using a Harvard
Apparatus model 975 compact infusion pump. The left ureter was then catheterised
with a short piece of PE·lO tubing fitted inside a length of PE·50 tubing. Urine was
collected between 20 and 40 minutes. At the end of the urine collection period, I-ml
blood samples were taken from the left renal vein and the abdominal aorta. Thc blood
samples were quickly spun in an Eppendorf centrifuge and the plasma retained. An
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aliquot of plasma (25 Ill) was used for the determination of inulin radioactivity.
Samples of urine (10 Ill) were treated in a similar manner.
2,11.1 Calculations
Glomerular filtration rate (GFR) was calculated from urinary inulin excretion
in the 20-40 min clearance period. Renal plasma flow was calculated using the
expression derived by Wolf (1941). The calculations th:n arc involvcd in the
measurement of renal plasma now and GFR are as follows:
I. VIP (inulin)"" inulin counts in urine (dpmlml)/ inulin counts in arterial plasma
(dpmlml).
2. GFR (mVrnin)= UIP (inulin) x urine flow rate (mllmin); thc ratc of excretion of
inulin is directly proportional to, and a linear function of, the plasma concentration of
inulin.
3. RPF=[(urinc (dpmlml»)/(arterial plasma (dpmlml) - renal venous plasma
(dpm/ml))] x urine flow rate
The values ofGFR, and renal plasma flow, arc multiplied by 2 (for 2 kidneys) and are
expressed as ml/min/l 00 g body weight.
2.12 Statisticalanal)'sis
All results are expressed as means ± standard deviation. Student's unpaired t-1est was
used to determine significant differences in studics with only two groups (Glucagon
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and PTU studies). In studies involving three or more experimental groups (Diabetic
and Thyroidectomy studies) one-way ANOVA, followed by Neurnan-Kcul mulliplc
means comparison test, was used to compare data. A value P< 0.05 was taken to
indicate a significant difference.
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Chapter 3: Homocysteine Metabolism in the H)'pothyroid Rat
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3.1 Background
A recent study by Nedrebo e/ al. (1998) investigated homocysteine status in
hypothyroid patients. They observed that total plasma homocysteine was elevated in
hypothyroid patients compared with healthy controls. Husscin e/ al. (1999) observed
that hypothyroid patients who received L-thyroxine trcatment have nonnal plasma
homocysteine. These observations are of particular importance since hypothyroid
patients have an increased risk for cardiovascular diseases (Stcinberg, 1968), which is
often attributed to elevated low-density lipoprotein cholesterol. However, altered lipid
levels do not fully explain the accelerated pathogenesis (Masaki el at., 1992; Ishikawa
e/al., 1989, Mamiya el at., 1989).
The present study was undertaken to investigate the role of thyroid hormones
on homocysteine metabolism in the rat. To this end, we utilised two hypothyroid
models.
3.2 The Hypothyroid Rat
Our first hypothyroid model was the propylth.iouracil.trcated rat.
Propylthiouracil, a thiocarbamide drug, is a potent inhibitor of the thyroid peroxidase,
an important enzyme involved in thyroid hOnTIone synthesis. In tbis study, rats (n=5)
received water containing 0.05% propylthiouracil (PTU) for 2 weeks, while a control
group of ten rats received untreated water (Helton and Magner, 1994).
In our second study, thyroidectomized and sham-operated fats were purchased
from Charles River, Montreal. Since the rats' parathyroid glands may have been
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damaged during the operation they reccived 0.1 % calcium gluconatc in the water
supply for the duration of the study. After 28 days, mini-osmotic pumps (MeLl,
Alzet, Ncwark, Del.) were placed subscapularly. The osmotic pumps placed in the
sham-operated rats and half of the thyroidectomized rats contained saline. The
remainder of the thyroidectomized rats received T4 (0.9 }ig/IOO g b.w.lday) and T3
(0. J5l!glIOO g b.w.lday). This regimen of thyroid hormone supplementation has been
shown to ensure euthyroidism in the thyroidectomized rat (Escobar-Morreale et af.,
1996). Homocysteine metabolism was examined 14 days after pump implantation.
There were 6 rats in each group.
3.2 Results
3.2.1 Propylthiouracil Study
Table 3.1 gives information on body weight, plasma thyroid honnonc and
plasma creatinine levels for the propylthiouracil experiment. The total plasma T, and
free plasma T4 concentrations were both decreased substantially in the PTU-treated
rals, thus establishing that they were hypothyroid. Plasma creatinine was unaltered
by PTU treatment suggcsting that kidney function was unaffected by hypothyroidism.
This is gennalle since plasma creatinine, an indirect index of glomerular filtration
mte, is positively correlated with homocysteine levels (Bostom et uf. 1995).
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Table 3.1. Body weight, plasma total T), and free T4 concentrations in
propylthiouracil~trcated and control rats.
Variable
Initial weight
Final weight
TotalT)
FrecT4
Creatinine
Units
,
oM
pM
Control(n 10)
312±13
4SS± II
O.80± 0.13
14.S± 1.9
63.7±7.S
PTU-treated (n S)
317± 12
370± 3S"
0.21 ±O.lS"
O.9±O.S"
59.9±9.8
Note: Data arc expressed as mean ± SO. " Represents significant difference
compared with controls. P< 0.05 (Student's t-test).
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Plasma total homocysteine levels were significantly decreased in the PIU-
treated rats compared to the controls: 6.86 ± 1.35 vs 11.54± 1.85 ~M (Fig 3.1). This
suggests that thyroid hormones may be involved in regulating plasma homocysteine
levels. Our next goal was to explain the observed decrease in homocysteine levels. A
decrease in plasma homocysteine concentrations could be explained by an increased
flux through enzymes of the transsulfuration and/or remethylation pathways. The
liver is the focal organ of amino acid metabolism and contains all of the relevant
enzymes (Finkelstein, 1990). The kidney appears to be the major organ involved in
homocysteine removal from plasma in the rat. In one pass, 20'% of plasma
homocysteine is removed by the kidney (Brosnan el at. 1995). Given the involvement
of these tissues in homocysteine metabolism, enzymes were assayed in both liver and
kidney. In the PTU-treated rat, there was a 70% increase in hepatic cystathionine p-
synthase activity; hepatic cystathionine y-lyasc activity was elevated approximately
two fold (Table 3.2). No difference was observed in liver methionine synthase and
betaine:homocysteine methyhransferase activity. Hepatic mcthylenetctrahydrofolate
reductase activity was decreased in the PTU-treated rats. These rcsults suggest that
the reduction of plasma homocysteine concentration was not the result of increased
activity of the remethylation pathway but they are consistent with increased flux
through the transsulfuration enzymes.
Unlike the liver, the kidney showed no increase in the activity of the
transsulfuration enzymes (Table 3.3). In fact, cystathionine y-lyase was somewhat
decrcased in the hypothyroid rat. There was also a small increase in renal methionine
Figure 3.1: Comparison of plasma total homocysteine concentrations in control
and PTU-treated rats. The asterisk represents significant difference (P<O.05,
Student'st-test).
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Table 3.2: Hepatic enzyme activities ofbomocysteine metabolism in P'TU-treated
and control rats.
Liver
Cystathionine trsvnthasc
Cystathionine x-lyase
Methionine svnthase
Methvlenetetrah)'drofolate reductase
Betaine:homocvsteine methyltransferase
Control(n 10)
2.89±0.S8
14.S ±4.1
0.22 ± 0.04
0.14 ± 0.03
4.71 ± 1.36
PTU·treated (n 5)
4.87±0.SO·
27A±3.S*
0.20 ±0.05
0.11 ±O.Ol*
4.33±0.6S
Note: All assays were performed on post-mitochondrial supernatant. Enzyme activity
is expressed as nmol/mg/min. Data arc expressed as means ± SD. The asterisk
signifies difference from control, P<0.05.
Table 3.3: Renal enzyme activities of homocysteine metabolism in PTU-treated
and control rats
Kidney
Cystathionine fJ--synthase
Cystathionine y-Iyase
Methionine s)"Dthase
Methylcnctetrahydrofolate reductase
Control (0-10)
1.71 ±0.58
5.30±0.79
0.65±0.04
0.45 ± O.Q7
PTU-treated (n~S)
l.81 ±0.78
4.04 ± 0.5\·
0.78±O.10·
0.49 ± O.Q3
Notc: All assays were pcrfonned on post-mitochondrial supernatant. Enzyme activity
is expressed as nmol/mg/min. Data are expressed as means ± SD. The asterisk
signifies difference from control, P<O.05.
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synthase activity in the PTU-treated rat. Methylenetetrahydrofolate reductase activity
was unchanged. Betaine-homocysteine methyltransferase is not present in the rat
kidney (Finkelstein, 1990).
3.2.2 Thyroidectomized Rat
Because these results were completely different from the human situation
(where hypothyroidism is associated with elevated plasma homocysteine) we
considered whether the PTU model might produce an artifactual result. We, therefore,
employed a different model of hypothyroidism- the thyroidectomized rat. Table 3.4
contains data concerning body weight, food intake. and plasma thyroid hormone
levels. Before insertion of the osmotic pumps, the thyroidectomized rats consumed
less food and were much smaller. Thyroid honnone replacement increased food
intake of the thyroidectomized rats, which grew at a rate similar to the control rats (5
glday). Total T] concentrations were nonnalised following thyroid honnone
replacement; however, free plasma T4 1cvels did not return to normal levels.
Total plasma homocysteine (Fig 3.2.) was also decreased in this hypothyroid
model (9.4 ± 0.6 in thyroidectomized rats compared with 14.5 ± 2.2 f.lM in controls).
Thyroid treatment restored homocysteine to control levels (13.2 ± 1.6 f.lM). This
strongly implicates thyroid honnone in the regulation of homocysteine metabolism.
As in the PTU·treated rats, the activities of liver cystathionine p-syntbase and
cystathionine y-Iyase were elevated in the hypothyroid rat (Table 3.5).
Mcthylcnetctrahydrofolale reductase activity was dl'Creased in the thyroidectomized
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Table 3.4: Body weight, total plasma TJ, and free T4 in thyroidectomized (±
thyroid treatment) and sham-operated control rats
Parameter Units Control Thyroidectomized Thyroid
treatment
Weight on dav 28 g 406 ±466 254±41" 252±23'
Final weight g 487 ± 57" 270± 15" 335±316
Food intake glday 31.S ± 2.4" 18.3 ±3.06 25.5±2.5"
Total plasma TJ nM 0.79 ± 0.096 0.49± 0.04" 0.78 ± 0.056
Frec plasma T4 pM 26.0 ± 4.46 5.84 ± 0.45' 9.06 ± 2.66"
Note: Initial weights of rats were equal for all groups (- 215 g). Data are expressed as
mean ± SO. Different superscripts within a horizontal row represent a statistically
significant difference among means (P< 0.05). There are 6 rats in each test group.
Figure 3.2: Comparison of total plasma homoC)'steine levels in thyroidectomized
(± thyroid treatment) and control rats. Columns with different letters (a,b) show
significant difference (one-way Anava, P<O.05).
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Table 3.5: Hepatic enzyme activities of homocysteine metabolism in
thyroidectomized (:I: thyroid treatment) and control rats.
Liver Control Thyroidectomized Thyroid
treatment
C)'stathionine (rsynthase 2.70 ± 0.646 4.86:1:0.49" 2.83±0.666
Cl'stathionine y-Iyase 14.9:1:3.1" 29.6:1:7.76 13.8±4.9"
Glycine N-methyltransfcrase 3,05± 1.09 2.34±0.70 2.2 ± 0.55
Methionine synthase 0.29± 0.09 0.38 ± 0.09 0.38±0.1I
Methy)cnecetrabydrofolace 0.24:1:0.08" 0.14:1:0.066 0.25 :1:0.07"
reductase
Betaine:Homocystcine 3.43 ±0.56 3,78± l.01 3.94 ± 0.95
methvltransferase
Note: All assays were pcrfonned on post-mitochondrial supernatant. Enzyme activity
is expressed as nmo1Jrnglmin. Data arc expressed as means ± SO. Different
superscripts within a horizontal row represent a statistically significant difference
among means (P< 0.05). There were 6 rats in each teSI group.
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rat. Thyroid treatment normalised the activity of these enzymes. No change in
lIctivity was observed in any of the oUIl:r liver enzymes measured.
The renal activity of methylenetetrahydrofolate reductase was reduced in the
thyroidectomized rat compared to the other groups. No change in renal activity of
cystathionine p-synthase or methionine syntbase was observed. Cystathionine y-
lyase was unaltered ill the thyroidectomized rat compared with controls. However,
enzyme activity was slightly increased in thyroid-treated rats (Table 3.6).
3.3 Discussion
The purpose of this study was to investigate homocysteine metabolism in the
hypothyroid rat in an effort to provide a metabolic explanation for increases in plasma
homocysteine in the human hypothyroid patient. However, the hypothyroid rat
exhibits decreased plasma homocysteine, unlike its human counterpart. [n order to
eliminate the possibility that the observed decreases in homocysteine werc an artefact
of a specific hypothyroid rat model, we examined both chemical and surgical models
of hypothyroidism. Similar decreases in plasma total homocysteine levels were
observed in bolh models. However, increased activitics of liver cystathionine P-
synthase and cystathionine y-lyase were observed in both hypothyroid rat models.
This result provides a possible explanation for the decrease in plasma homocysteine
concentration. Thyroid hormone administration to thyroidectomized rats normalised
the activitics of both transsulfuration enzymes and plasma homocysteinc levels,
Table 3.6: Renal enzyme activities of homocysteine metabolism in
thyroidectomized (± thyroid treatment) and control rats.
IGdney Control Thyroidectomized Thyroid
treatment
Cvstathionine 6-svnthase
Cystathionine x-lyase
Methionine synthase
Methylenetctrahydrofolate
reductase
1.09±0.35 1.42±O.62
7.9±2.0" 6.2± 1.1"
0.91 ±0.06 0.90±O.16
0.67 ± 0.076 0.47 ± 0.5"
J.21 ±0.43
9.9± 1.66
0.97±0.14
0.65 ±0.176
Note: All assays were performed on post-mitochondrial supernatant. Enzyme activity
is expressed as nmoUmgimin. Data are expressed as means ± SO. Different
superscript<; within a horizontal row represent a statistically significant difference
among means (1)< 0.05). There were 6 rats in each tcst group.
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providing further evidence for the role of thyroid honnonc in regulating
homocysteine metabolism.
The reason (or reasons) for the discrepancy between the hypothyroid human
and rat is not readily apparent, although differences in kidney function may provide a
plausible explanation. Nedrebo et aJ. (200 I) observed parallel changes in serum
creatinine and total homocysteine, suggesting that decreased renal filtration may
account for the elevation in plasma homocysteine in the human hypothyroid patient.
Some studies have reported decreased GFR in tbe hypothyroid rat; however, in our
study, plasma creatinine levels were unallered by PTU-trefltmenL This may be
explained by the relatively short (2 weeks) hypothyroid period. One could
hypothesize that a longer treatment period might result in decreased GFR and
hypcrhomocysteinemia in the PTU-treated rat. However, this issue was not addressed.
11 is also conceivable that the honnonal control of gene expression of the
transsulfuration enzymes ditTer between the two species. In this connection
Ingenbleek et al. (1986) reported a decrease in plasma cystathionine levels in
hypothyroid patients and suggested that this may be related to a deficiency in
cystathionine ~-synthase. However, this observation could also be explained by
increased cystathionine y-Iyase as was seen in this study. This issue may be resolved
by comparative studies on the effect of thyroid homlOne on the expression of these
enzymes in human and rat hepatoma cells.
Although we have strong evidence for the involvement of the hepatic
transsulfuration pathway in reducing plasma homocysteine in the hypothyroid rat, we
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cannot exclude the possibility of elevated remethylation of homocysteine to
methionine. One argument against this possibility is the consistent decrease in
methyleneletrahydrofolale reductase activity in the hypothyroid rat, a result also
observed in other studies (Nair et al., 1994; Keating et al., 1988). The activity of
methionine adenosyltransferase has been shown by Keating et al. (1988) to be
elevated in hypothyroidism, resulting in enhanccd levels of S-adenosylmcthionine
(SAM). S-adenosylmethionine is a known allosteric inhibitor of
methylenetetrahydrofoJate reductase and an activator of CBS (Finkelstein, 1990)
Thus, an increase in SAM would favour transsulfuration over remethylation. These
findings argue against elevated remethylation in the hypothyroid rat.
The actions of thyroid honnone are primarily the result of the interaction ofT)
with nuclear receptors that bind to regulatory regions of genes and modify their
expression (reviewed in Brent, 1994). It is therefore possible that Ihe expression of
cystathionine p-synthase and cystathionine y-Iyase genes is induced during
hypothyroidism. However, the changes occurring in hypothyroid rats may be
secondary to changes in other factors. Cell culture studies are necessary to resolve
this issue
To our knowledge this is the first study that examines homocysteine
metabolism and its enzymes in an experimental model of hypothyroidism. We have
shown that homocysteine concentrations arc consistently decreased in thc
hypothyroid rat, and this decrease is associated with increased enzyme activities of
the hepatic transsulfuration pathway. Nonnalization ofthesc parameters after thyroid
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replacement emphasises the importance of thyroid Slatus in homocysteine
melabolism. As it is apparent that hypothyroidism in the rat is not a good model for
human hypothyroidism we did not pursue this model any further.
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Chapter 4: The streptozotocin-diabetic rat
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4.1 Background
Cardiovascular diseases arc the major cause of death in diabetic patients (Fein
and Scheuer, 1990), and there has recently been much interest in the possible role of
homocysteine in the development of cardiovascular diseases in these patients
(Schneede el 01., 2000). Homocysteine levels in human diabetic patients appear to
dcpend on the presence or absence of nephropathy. Diabetic patients with elevated
creatinine levels (an indicator of kidney dysfunction) tend to exhibit an increase in
plasma homocysteine (Hultberg et al., 1991). This is consistent with studies that show
tbat the kidney is an important organ in the removal of plasma homocysteine (Bostom
et al., 1996). On the other hand, type I patients with normal creatinine levels have
decreased plasma homocysteine (Robillon el 01., 1994). The explanation for
decreased homocysteine concentrations is unknown in these cases. but the regulation
of homocysteine metabolism by insulin could afford an explanation.
The purpose of this study, therefore, was to examine homocysteine
metabolism in a diabetic rat model and to determine whether insulin plays a role in its
regulation. For several decades, streptozotocin, an analogue ofN-acetylglucosamine,
has been used to cause pancreatic fJ-cell death and tbe subsequent development of
Type I diabetes (Konrad et al.• 2001). Thus the streptozotocin-diabetic rat provides
us with a useful tool in studying homocysteine metabolism in Type I diabetes
mellitus.
>0,
4.2 The streptozotocin-diabetic rat
Diabetes was induced by a single intmvenous (tail vein) injection of 100
mglkg streptozotocin (dissolved in 10 mM citrate buffer, pH 4.5 immediately before
use) under light ether anaesthesia, while control rats were administered an equal
volume of citmte buffer. Half of the diabetic rats (diabetic untreated) were treated
with Novolin®ge ultralente human insulin (Eli Lilly, Indianapolis) subcutaneously
for 5 days, whereupon insulin was withdrawn and they received saline injections for 5
days (n=8). The remaining diabetic rats (diabetic treated) received insulin injections
for the entire 10 days of the experiment (n:8). The control group received saline
injections (n"'8). Insulin was administered at 9:00 and 19:00h; the dose was adjusted
so as to maintain blood glucose close to control values as measured with an Ames
glucomcter n, using a drop of blood obtained by tail prick.
Tissuc sampling and experimental procedures are as oullined in Chapter 2.
Variations in experimental designs are indicated, when nccessary, throughout the
Results section.
4.3 RESULTS
4.3.1 The streptozotocin-diabetic rat model
Table 4.1 gives infonnation un body weight, food intake, plasma glucose and
creatinine. Although the final body weights differed, there were no differences in
food intake among groups. Given that the groups consumed similar quantities of
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TABLE 4.1: Body weight, food Intake and plasma glucose and creatinine
concentrations in control, diabetic, and insulin-treated diabetic rats.
Untreated Insulin-treated
Control Diabetic Diabetic
Initial Weight (g) 316± 17" 31S± IS' 313 ±23"
Final Weight (g) 36S±22c 27S± IS" 313 ±27b
Food Intake (glday) 27±4.1" 30 ± 9.4" 2S±4.0"
Plasma Glucose (mM) 7.6± 1.2" 34.8±3.Sb 7.4± 1.7"
Plasma Creatinine (11M) 81 ±S.9b 61 ±4.8" 79± 7.2"
Food intake was dctennined daily. Glucose and creatinine measurements were made
on day 10, i.e. at the end of the experimental period. Data are expressed as means ±
SD. Different superscripts within a horizontal row represent a statistically significant
difference among means (P< 0.05).
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food, we cannot attribute alterations in homocysteine metabolism to differences ;n
vitamin or amino acid inlakes. The plasma glucose in the untreated diabetic rat
demonstrates frank diabetes which was well controlled by insulin treatment in the
diabetic treated group. Plasma creatinine levels in the untreated·diabetic rats were
not elevated; in fact, they were slightly lower than the other groups, indicating that
renal function was not impaired in the diabetic rats. The decrease In creatinine
concentration may be attributed to hyperfiltration.
4,3.2 Effect ofstreptozotocin and insulin treatment on plasma homocysteine
The question posed is whether streptozotocin.;nduced diabetes results in
decreased plasma homocysteine levels as observed in the human diabetic patient.
Connected to this question is whether daily insulin administration could prevent any
observed decrease and whether we could provide a satisfactory explanation for
altered homocysteine metabolism. Plasma homocysteine levels in the streptozotocin·
induced diabetic rats were approximately 40% lower than in the controls (diabetic
untreated vs control; 6.97 ± 1.17 vs 10.91 ± t.141J.M, P < 0.05) [Fig. 4.1]. Insulin
treatment prevented the decrease in the plasma homocysteine concentrations in
diabetic rats (10.33 ± 0.56 11M). This is the first evidence to suggest that insulin may
playa role in regulating plasma homocysteine levels.
We measured urinary homocysteine to determine whether the decreased
plasma homocysteine in diabetes could be due to increased urinary loss. Figure 4.2
shows no significant difference in the quantity of homocysteine excreted per day
Figure 4.1: Comparison of total plasma homocysteine tn control, untreated
diabetic aDd insulin·treated diabetic rats. Data are expressed as means ± SO. The
difference in letters among columns signifies differences (P<O.05) between groups.
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among the three groups. Bostom et at. (1995) showed that only 2% of the total
homocysteine removed by the rat kidney appears in the urine. Thus homocysteine
excretion does not represent a major route of homocysteine loss from the body and it
is not increased by untreated diabetes.
4.3.3 Effect of streptozotocin~induccddiabetes and insulin~trellltmcnton hepatic
and renal enzyme activities
The liver is a major organ in methionine metabolism, as evidenced by the
distribution and specific activities of the enzymes of methionine metabolism as well
as ilS role in creatine synthesis, the major methyl requiring reaction in the body
(Stipanuk, 1986). Although unproven, the liver is likely the major producer of
plasma homocysteine. Svardal el at. (1986) have shown that hepatocytes release
homocysteine into their culture ml-dium. We, therefore, measured the activities of the
enzymes in the transulfuration and remethylation pathways in the liver.
Increases in hepatic activities of enzymes involved in the catabolism of
methionine to cysteine are seen in the untreated-diabetic rat. Methionine
adenosyltransferase, glycine N-methyhransferase, and cystathionine p-synthase
activity increased 30% while cystathionine y-lyase activity was elevated two-fold in
liver (Table 4.2). Insulin treatment prevented the increases in the activities ofthesc
enzymes. No difference was observed in the activities of methionine synthase,
methylenetetrahydrofolatc reductase and betainc:homocysteinc methyltransfcrasc,
109
TABLE 4.2: Activities of hepatic enzymes involved in methionine and
homocysteine metabolism
Untreated Insulin-Treated
Control Diabetic Diabetic
Methionine adenos}'ltransferase l.00 ± 0.06" 1.30±0.IOb 0.99 ± 0.08"
Glycine N-methyltransferase \.0 ± O.OS" I.2S±O.IOb 0,95±0.lS"
Cystathionine p-synthase 0.70 ± 0.10" 0.98±0.3I b 0.68±0.14"
Cystathionine y-Iyase IOA± IS 22.S±0.9b 1O.0± 1.3"
l\1elhioninesynthase 0.08 ± 0.01" 0.07±0.01" 0.08 ± 0.02"
Betaine:homoeysteine
mcthyltransferase 3.2 ± 0.3" 4.1::l: 1.4' 2.9± 1.0"
Methylenetctrahydrofolate
reductase 0.33 ±0.06" 0.26± 0.07" 0.2S±0.OS'
All assays were perfonned on post-mitochondrial supernatant. Enzyme activity is
expressed as nmol/mg protein/min. Data arc expressed as means ± SO. Different
superscripts within a horizontal row represent a statistically significant difference
among means (P< O.OS).
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suggesting that the reduction of plasma homocysteine was not the result of an
activation of one of the remethylation pathways. These data suggest an importan!
role for the hepatic transsulfuration pathway in diabetes and also suggest a role for
insulin in regulating this pathway.
Patients with end-stage renal disease nave increased plasma homocysteine
concentrations (Bostom and Lathrop, 1997). Rat renal tubular cells possess enzymes
for both remethylation and transsulfuration of homocysteine (House el al., 1999).
Furthermore, our lab reported a significant, positive arteriovenous difference for
homocysteine across the rat kidney, representing 20% of the arterial plasma
concentration (Brosnan et at., 1995). Given the importance of kidney metabolism in
regulating plasma homocysteine and the fact tnat alterations in kidney function are a
common complication in diabetes we performed two separate experiments. First, we
measured the activities of renal enzymes involved in homocysteine metabolism and
secondly we measured renal homocysteine uptake in the strcptozotocin-diabetic mt.
Unlike the liver, the activity of the renal transsulfuration enzymes in the
kidney did not change (Table 4.3). A decrease in renal methionine synthase activity
was observed in the diabetic rats, which was normalized by insulin treatment. The
renal activity of methylenctctrahydrofolate reductase was decreased in the diabetic
rats and this was not corrected by insulin treatment. Betaine:homocysteine
methyltransferase is not found in the rat kidney.
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TABLE 4.3: Renal Activities of enzymes of homocysteine metabolism.
Untreated Insulin~Treated
Control Diabetic Diabetic
Cystathionine p-synthase 0.36 ± 0.05' 0.35 ± O.OS· 0.35 ± 0.09'
Cystathionine y~lyase 6.2± 1.1" 6.4± 1.9" S.S± 1.4'
Methionine synthase 0.34±0.03b 0.25±0.01" 0.36 ± O.04b
Methylcnetetrahydrofoillte 0.79 ± 0.07b 0.24 ± O.OS" 0.33 ±0.O6"
reductase
All assays were performed Oil post-mitochondrial supernatant. Enzyme activity is
expressed as nmol/mg protein/min. Data arc means ± SO. Different superscripts
within a horizontal row represent a statistically significant difference among means
(P<O.05).
4.3.4 Effect ofstrcptozotocin on renal homocysteine flux
Even tbough the activities of the renal transsulfuration enzymes were nonnal
in the streptozotocin-diabetic rat, the kidney still could be responsible for the decrease
in plasma homocysteine in the diabetic rat Many studies in humans have shovm that
plasma homocysteine correlates inversely with GFR (Amadottir et al., 1996). In our
study, plasma creatinine was decreased in the diabelic rat suggesting an increase in
GFR. If this were the case, increased renal metabolism may be responsible for the
decreased plasma homocysteine in the diabetic rat. To address this possibility, we
measured the renal homocysteine flux in both diabetic and control rats. If the kidneys
were responsible for the decreased plasma homocysteine we would expect to observe
an increase in renal homocysteine flux in the diabetic rat.
Renal bemodynamic parameters are presented in Table 4.4. No significant
eITect of diabetes on glomerular filtration rate or renal plasma flow occured, which is
inconsistent with our plasma creatinine data. Not surprisingly, thc urine flow was
increased 5-fold in the untreated-diabetic rat versus controls. As a result of increased
urination, the U:P ratio for the diabetic rat was reduced by 75%.
Table 4.5 shows the results of our studies of rcnal homocysteine metabolism
in diabetes in vivo. We observed a constant, positive arteriovenous difference for
homocysteine concentration, equivalent to approximately 15% of the total arterial
plasma homocysteine concentration. In no case did we find a zero or negative
arteriovenous differencc. Consistent with previous measurements from our
laboratory, ratcs of homocystcinc excretion wcre low «2% of total loads),
Table 4.4: Renal hemodynamic parameters of diabetic and control rats
Parameter Units Control Untreated
Diabetic
Body weight grams 370±40 300±8.0*
Urine flow ~/minilOOg 4.5± 1.1 26.6±2.8*
U:P ratio for inulin 195±80 41 ± 10*
Glomerular filtration mUminllOOg O.83±O.21 1.I ±O.I
rate
Renal plasma flow mUmin/IOOg 3.5±O.4 4.1 ±O.9
Values are expressed as means ± SD (n=4). Asterisks represents significant difference
from controls (Student's t-test, P<O.05).
Table 4.5: In vivo renal homocysteine metabolism in diabetic and control rats.
Parameter Units Control Untreated
Diabetic
Arterial
""
6.7± l.0 2.9± 1.0·
Homocysteine
A-V .M 1.04 ± 0.30 OA7±0.IS·
Difference
Net Renal '1moleslmin/lOOg 3.7± 1.2 1.8±OA*
Homo<-vsteineFlux
Homocysteine '1moles/min/IOOg 0.Q7±0.02 0.06± 0.02
Excretion
Values arc expressed as means ± SD (n==4). Asterisks indicates significant difference
from controls (Student's t-test, P<O.05). Net renal homocysteine flux was calculated
as the product of the A-V difference and the rcnal plasma flow.
lIS
which illustrales that Ihe bulk of the homocysteine taken up by the kidney is
metabolized. The renal homocysteine flux was decreased by 50% in the diabetic rat
versus control. This value reflects the 50% decrease in A-V difference for
homocysteine concentration in the diabetic ral as the renal plasma flow was
unchanged compared to controls values. These data provide direct evidence that the
kidneys are not responsible for the decreased plasma homocysteine levels in the
diabetic rat.
4.3.5 Effects offasting on homocysteine metabolism in the diabetic rat
Thc results of these experiments suggest that the decreased plasma
homocysteine, observed in the untreated-diabetic rat, could be due 10 increased
catabolism via the hepatic transsulfuration pathway. However, these experiments
were performed on fed animals, which favour transsulfuration flux over the
remethylation pathway. We therefore, perfonned the same experiment on 24 hour
fasted rats. In this study insulin was not administered to the diabetic rats due to the
risk of hypoglycaemia even though plasma glucose was elevated 40% in the diabetic
ral(Figure4.3).
As in the first experiment, plasma homocysteine was decreased in the diabetic
rat versus controls (Figure 4.3). The hepatic enzyme activities involved in
homocysteine metabolism were again measured (Table 4.6). Again, we observed
increased enzyme activities of the hepatic transsulfuration pathway, while no change
was found in the remethylation enzyme activities. This provides further evidence for
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Figure 4.3: Plasma glucose and total plasma homocysteine concentrations
following a 24·hour fast in control and untreated diabetic rats. Data are expressed
as means ± SO. An asterisk indicates a significant difference between groups, P<O.05.
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Figul"e 4.4: Hepatic enzyme activities in control and diabetic rats following a 24
hOUI" fast.
Contl"ol Untreated
Diabetic
Cystathionine p-Synthase 2.99±O.51 4.44 ± 0.96'*
Cystathionine Y-L)'ase 13.3 ±2A 20.6±0.9S·
Methionine Synthase 0.11 ±0.03 0.14±0.04
Betaine:Homocysteine 2.71 ±OA5 2.76±0.62
Methyltransferase
Methylenetetrahydrofolate Reductase 0.20 ± 0.03 0.22 ± 0.02
All assays were perfonned on post-mitochondrial supemalant. Enzyme activilY is
expressed as nmol/mg protein/min. Data arc means ± SO (n=5). Asterisk indicates a
significant difference between groups, P<O.05.
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the importance of the hepatic transsulfuration pathway in regulating plasma
homocysteine in the diabetic rat.
4.3.6 Regulation of plasma homocysteine and hepatic cystathionine p.s}'nthasl'
by insulin
We next examined the time-course of insulin's effect on homocysteine
metabolism in diabetic rats. Diabetic rats were without insulin for 5 days, al which
point insulin was administered for I, 3, or 5 days. Rats ate a commercially obtained
rodent diet ad libitllm and had free lIecess to water. Diabetes was induced as outlined
previously in this chapter.
Figure 4.4 shows the time-course of the insulin effect on plasma
homocysteine in the diabetic rat. Plasma homocysteine was decreased by 60% in the
untreated diabetic rat versus controls. Insulin treatment increased plasma
homocysteine in the diabetic rat within I day. However, plasma homocysteine did nOI
return to control values. This is noteworthy since insulin did normalize plasma
homocysteine in our previous experiments. Plasma glucose was normalii'..cd following
insulin treatment Ihus dismissing the possibility Ihal the rats were nOI properly
insulinized (Figure 4.4). Since diabetes is characterized by decreased circulating
insulin and increased circulating glucagon levels, we also measured plasma glucagon
concentrations in control, diabetic and insulin-treated (5-days) diabetic rats (Figure
4.5). Plasma glucagon was elevated by 40% in the untreated diabetic rat versus
controls; however, insulin treatment failed to return glucagon levels to normal. The
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Figure 4.4: [(fect of insulin treatment on plasma glucose and total plasma
homocysteine levels in the streptozotocin.diabetic rat. Diabetic rats were treated
with insulin for 0, 1,3 or 5 days. Data are expressed as means ± SO. Differences in
leiters (a,b,c) between columns signify differences between group means. (n= 4·6)
40
"Ul8 30
5~
'" E 20E-
Ul
.!S! 10
Q.
10.0
.
c
l~ 7.5
0;;1.. 5.0
",-
2.5
OO,LJ_.L.J._L
III
Figure 4.5: Comparison of plasma glucagon levels in control, untreated diabetic,
and insulin-treated diabetic rats. Data are expressed as means ± SD. Differences in
leuers (a,b) between columns signify difference between group means.
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increased glucagotllevels may also offer an explanation why homocysteine levels did
not completely normalize following insulin treatment.
Hepatic cystathionine ~-synthase activity was elevated in the untreated
diabetic rat (Figure 4.6) and treatment of these rats with insulin for I day decreased
the activity of cystathionine ~-synthase to comrollevels. To determine whether these
observed changes in cystathionine ~-synthase enzyme activil)' were regulated at the
level of transcription, we measured cystathionine ~synthase mRNA levels in rat
livCf. When normalized for ~-actin mRNA, hepatic cystathionine ~-synthase mRNA
from the untreated diabetic rats was elevated by 2-fold versus controls (Figure 4.7).
Insulin treatment decreased the level of cystathionine ~-synthase mRNA to nearly
40'% of that in the untreated diabetic rat within a day. This level fluctuated little in the
3- and 5-day insulin-treated groups.
4.3.7 Hormonal regulation of cystathionine p-synlhase in H4IIE cells
To determine whether the effects of insulin in vivo on CBS expression would
be evident in vitro and whether countcr-regulatory hormones might playa role, we
examined the cffects of hormones on CBS in rat hepatoma (H4I1E) cells. CBS
activity increased by 50% in cell extracts obtained from H411E cells following an 8
hour treatment with triamcinolone (a glucocorticoid analogue) (Figure 4.8). This
increase in enzyme activity was blocked when cells were co-incubated in the presence
of insulin.
Figure 4.6: Effect of insulin treatment on hepatic c)'stathionine beta-s)'nthase
activity in the diabetic rat. Diabetic rats, which were insulin-deficient for 5 days
were treated with insulin for O. I. 3 or 5 days. Data are expressed as means ± SO.
Differences in letters (a,b,c) between colullUlS signifY difference between groups.
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Figure 4.7: Northern Blot BnBlyses ofhepBtic cystBthionine betB-synthase mRNA
levels in control, diabetic, and insulin-treated (1,3, and 5 dBys) diabetic rats.
Total RNA, isolated from freeze-clamped livers, was separated on a 1%
agaroselfonnaldehyde gel and transferred to a Nylon membrane. Cystathionine .B-
synthase and .B-aelin mRNA levcls were detennincd by Northern BIoI analysis.
AB
cps
p-Actin
Control Diabetic
Days of Insulin Treatment
129
4.8 Effect of triamcinolone (TMC) and insulin (INS) incubation on cystathionine
beta-synthase activity in H4IIE cells. Data are expressed as means ± SD.
Differences in letters (a,b) between columns signify difference between groups
(P<O.05).
7.5
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To verify thai the triamcinolone-induced increase in cystathionine Jkynthase
enzyme activity was a refleclion of an increased amouni of CBS protein, cellular
lysates were separ.lted by SDS·PAGE with the amount of cystathionine ~synthasc
protein detennined by Western Blot analysis (performed in collaboration with Dr.
Shobhitha Ratnam). The level of cystathionine ~synthase protein increased with
increasing triamcinolone with maximal levels reached at a concentration of I 11M
(Figure 4.9a). H411E cells were then stimulated by a fixed concentration of
triamcinolone (100 nM) in the presence of various doses of insulin (10 nM to 111M).
TIle glucocorticoid-stimulated increase in CBS protein was partially inhibited by 10
nM insulin and was completely inhibited by 50 nM (Figure 4.9b). Incubation with
insulin alone showed no significant changes in the basal expression of cystathionine
~synthase protein in these cells.
To investigate whelber the hormone-dependent regulation of cystathionine jl..
synthase protein and activity levels was associated with relative changes in CBS
mRNA, total RNA was isolated from H41lE cells. Following RT.pcR, the DNA
products (CBS and jl-.actin) were separated on an agarose gel and analyzed by
Southern blotting (performed in collaboration with Dr. Shobhitha Ratnam). Control
cells expressed low levels of CBS mRNA which was increased by 3-4 fold by
triamcinolone (Figure 4.10, lane 2). This glucocorticoid-dependent induction was
completely inhibited by insulin (Figure 4.10, lane 3). When cells were incubated with
a cyclic-AMP analogue (CPT..cAMP) there was a 1.5-2 fold increase in CBS mRNA
which was also suppressed by insulin (Figure 4.10, lane 4). Co-incubation of cAMP
Figure 4.9: Cystathionine beta-synthase protein levels in H41IE cells. CBS protein
was measured by Western Blot. A. Effect of increasing concentration of
triamcinolone. Lane I, Control, Lanes 2-5: triamcinolone, 10,50,100 and 1000 nM;
lane 6, DMSO control; Lane 7, Biotinylated molecular weight standards. B.
Suppression ofCSS protein by insulin incubation. Cells were stimulated with 100 nM
triamcinolone and increasing concentrations of insulin. Lane I, triamcinolone (100
nM); lanes 2.6, triamcinolone (100 mM) and insulin 1, 10, 50, 100, 1000 nM,
respectively; Lane 7, biotinylated molccular weight standard.
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Figure 4.10 Effect of hormone treatment on cystathionine beta-synthase mRNA
levels in H4IIE cells. RNA (2 Ilg) was reverse transcribed and amplified. Southern
blot of the PCR products probed with n p labeled CBS cDNA and ~-actin cDNA. A.
Lane I, control; lane 2. triamcinolone (IIlM); lane 3. uiamcinoione (IIlM) + insulin
(I IlM); Jane 4, CPT cAMP (200 !!M), lane 5, CPT cAMP + Insulin (I ~; lane 6,
glucagon (IIlM); lane, 7, glucagon (lIlM) + Insulin (I IlM); lane 8, triamcinolone (J
IlM) +CPT cAMP (200 J.tM); lane 9, triamcinolone (J 11M) + CPT cAMP (200 J.tM)
+ Insulin (I IlM); lane. 10, insulin (I J.tM), 8. Graph rcpresenlS densitometric
quantitation of CDS mRNA when nonnalized for ~-actin. Data represented arc mean
± standard deviation (3-5 experiments).
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and triamcinolone did not have an additive effect (Figure 10, lane 8). Furthennore,
the addition of glucagon to the medium was without effect (Figure 4.10, lane 6); this
was possibly due to the common loss of glucagon nx:eptors on hepatoma cells
(Fehlmann ef al., 1983). Finally, when cells were incubated with insulin alonc,
constitutive expression ofeBS mRNA was unaltered (Figure 4.10, lane 10).
4.4 Diseussion
Destruction of l3-cells causesType I diabetes mellitus, due to cessation of
insulin synthesis and secretion. The effects of insulin deficiency on fuel metabolism
havc been well documentw (Ellenberg and Rifkin, 1990). Hyperglycemia, a
chamcteristic finding, arises from glucose underutilization in peripheral tissues
(muscle and adipose) together with hepatic overproduction. Elevated lipolysis from
adipocytes increases plasma fatty acids and hepatic ketogenesis. Similarly, muscle
protcolysis results in increased release of amino acids, mainly alanine and glutamine,
into the plasma. Furthcnnore, hepatic uptake of gluconeogenic amino acids is
increased and urea synthesis sharply elevated in the diabetic rat. Increased catabolism
of the most quantitatively important amino acid, glutamine, has been observed in our
laboratory. Hepatic glutaminase was induced and activated in the diabetic liver
(Brosnan et at., 1995). [n addition, insulin treatment returned glutamine catabolism to
control values, as measured by flux through glutaminase. That study illustrated the
importance of insulin in regulating glutamine metabolism and a similar regulatory
effect seems to be important in homocysteine metabolism.
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Plasma homocysteine is decreased in the slreptozotoein-diabetic rat. This
finding is consistent with human Type I patients with nonnal kidney function
(Robillon et al., 1994). Given the importance of renal homocysteine metabolism, it
was vital to ascertain the role of the kidney in the regulation of plasma homocysteine
levels. The activities of the renal transsulfuration enzymes, the major mechanism for
homocysteine removal by the kidney (House et al., 1998), were unaltered in the
diabetic rat. Furthermore, renal homocysteine flux (an accurate measurement of the
amount of homocysteine metabolized by the kidneys) was decreased in the diabetic
rat. Together, these data provide convincing evidence that altered renal homocystcinc
handling was not the cause of the decreased plasma homocysteine in thc diabetic rat.
Investigating thc hepatic enzyme activities did shed some light on thc possible
mechanism responsible for the altered plasma homocysteine. The deereasc in plasma
homocystcine was associated with increased activities of the cnzymes that convert
methionine to cysteinc. Insulin treatment normalized the activity of these hepatic
enzymes and elevated the level of plasma homocysteine, emphasizing the importancc
of insulin in homocysteine metabolism. The increascd activity of methionine
adenosyltransferasc (the first step in methionine metabolism) and cystathionine ~­
synthase (the first committed step in homocysteine clltabo!ism) may be vital for the
increased conversion of methionine to cysteine in the diabetic rat. The hormonal
regulation of these enzymes has now been characterized and they respond similarly to
insulin and its counter-regulatory hormones.
1J8
In this study, we have investigated the hormonal regulation of cystathionine ~­
synthase in dctail. CBS mRNA and activity arc elevated in the untreated*diabelic rat.
Insulin administration represses CBS mRNA levels in vivo. The role of countcr-
regulatory honnones was observed in cultured hepatoma cclls where triamcinolone
increased the level of CBS mRNA, protein and activity. This is consistent with an
early study by Goss (1986) who showed thaI CBS activity in hepatoma cells is
increased by the combination of dexamethasone and agents that raise intracellular
cAMP levels. Glucocorticoids excrt their metabolic effeclS primarily by changing the
transcription rate of gencs (Beato, 1989; Lee and Tsai, 1994); however they also
increase mRNA stability anrllor transport to the cytoplasm (Nielsen and Shapiro,
1990). Our laboratory is currently investigating how glucoconicoids stimulate CBS.
Although we did not observe any additive effect of TMC and CPT-cAMP it is
possible that the actions of glucagon (along with glucocorticoids) play an important
role in the induction of this enzyme. Indeed, Chapter 5 describes a plcthora of in
vivo effects elicited by glucagon on hepatic CBS.
We have shown that insulin inhibilS CBS in vivo and in vitro. The mechanism
by which insulin represses glucocorticoid and cAMP-mediated gene expression is
complicated and poorly understood. The hormonal regulation of
phosphoenolpyruvate carboxykinase (the rate limiting step in hepatic
gluconeogenesis) gene expression has been well characterized (Sasaki et aI., 1984;
Schuban, 1986). The rate of transcription of hepatic PEPCK is stimulated by cAMP
and glucoconicoids and is inhibited by insulin (Forest et at., 1990). Insulin primarily
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inhibits the initiation of PEPCK gene expression but also reduces the rate of transcript
elongation (Scott el al., 1998; Stafford CI al., 200 I). Furthennore, the action of insulin
was shown to be dominant over cAMP and glucocorticoids (a characteristic shared
with cystathionine ~.synthase) (Sasaki el aL, 1984). Recent studies have suggested
that insulin may inhibit glucocorticoid stimulated PEPCK gene transcription by
interfering with the binding of transcription factors to the steroid response clement
(O'Brien and Granner, 1996). Similar regulation has been observed for tyrosine
aminotransferase (Ganss el al., 1994). Insulin may also activate enzymes that degrade
the glucocorticoid receptor, thus linking insulin and glucocorticoid signalling (Kupfcr
et al., 1994). Whether the regulation of cystathionine ~-synthase gene expression is
similar to that of PEPCK is unclear. However, it should be noted that the insulin
response sequence (T(G/A)1TT(T/G)(Grr) present on the promoters of PEPCK and
tyrosine aminotransferase (O'Brien and Granner, 1996) is present on the human CBS
gene promoter (-4430 downstream with respect to the stan codon). Upon analysis,
this sequence was also found on the 5' untranslated region of the rat CBS gene.
The methionine adcnosyltransfcrase response 10 insulin and glucocorticoid
levels is similar to that or CBS. The honnonal regulation of MAT was first observed
in adrenalectomized animals in the late 1960s (Pan and Tarver, 1967). However the
mechanism for such regulation would remain obscure until the late 1990s when Gil el
al. (1997) presented convincing evidence that glucocorticoids modulate this enzyme
both in vivo and in hepatoma cells. Following adrenalectomy in the ral, enzyme
activity, protein and rnRNA levels were all decreased. When these animals were
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treated with triamcinolone all 3 parameters were nonnalized. Triamcinolone also
increased MAT mRNA content in culture cells. This increase in mRNA levels was
dependent on induction of the MAT gene since actinomycin 0 abolished the effects
of triamcinolone. Gil el al. (1997) also showed that insulin could block the inducing
effects of glucocorticoids on MAT mRNA. The coordinated regulation of MAT and
CBS may have importance during periods of stress and trauma. In such situations
elevated glucocorticoids may stimulate nux through the transsulfuration pathway.
The increased supply of cysteine may hclp maintain the glutathione pool thus
preventing oxidative damage. Methionine transsulfuration is increased in the septic
rat. Glucocorticoids are often elevated in sepsis which may provide a mechanism for
the increased conversion of methionine to cysteine.
Our in vivo data suggest that flux through the hepatic transsulfuration pathway
is increased in the diabetic rat. Our earlier work showed that the hepatic level of
methionine is markedly reduced in diabetic rat liver while the hepatic level of
cysteine is increased 3-fold, which is consistent with increased flux through the
transsulfuration pathway in the diabetic liver (Brosnan el a/., 1983). We have
described an induction ofeSS in the untreated-diabetic rat, which would increase the
capacity of the transsulfuration pathway and may explain any increase flux through
this pathway. It is, of course, also possible that increased transsulfuration flux in the
diabetic rat would be due to the activation of the cystathionine p-synthase in addition
to induction. The actions of many honnones, including glucagon and epinephrine,
occur through phosphorylation of cellular proteins. Such an effect has been described
in in vitro studies of MAT which have shown that this enzyme can be phosphorylated
(Pajares er al., 1994). Indeed, there are at leaSI 12 different putative phosphorylation
motifs in the rat-liver MAT sequence (Pajares er al., 1992). Cystathionine ~-synthase
also contains a phosphorylation (Protein Kinase A) consensus sequence; however,
phosphorylation of this enzyme has yet to be shown. Allosteric regulation may play
an important role in increasing the nux through cystathionine ~-synthase in the
diabetic rat. Cabrero er aI., (1986) showed a 35·fold increase in the total hepatic S-
adenosylmethioninc/S-adenosylliomocysteine concentrations in the alloxan-treated
rat. These nucleotides activate cystathionine ~-synthasc while inhibiting
remethylation which would favour nux through the transsulfuration pathway
(Finkelstein and Martin, 1986). Additional work is necessary to determine the
importance of the other mechanisms in our diabetic rat model.
In the diabetic state, the absence of insulin and the increased levels of
glucagon signal the liver to supply the body with glucose through glycogenolysis and
gluconeogenesis from amino acids released from muscle (Ellenberg and Rifkin,
1990). Pyruvate is the carbon product of cysteine metabolism and is a good
gluconeogenic precursor. In view of insulin's well-established role in inhibiting
gluconeogenesis and given its inhibitory effects on the hepatic transsulfuration
pathway, we suggest that glucose is the likely end product of sulfur amino acid
metabolism in the diabetic rat liver.
This study provides convincing evidence thai plasma homocysteine
concentration is decreased in the Type I diabetic rat. Collectively, these findings offer
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the first demonstration that insulin has a possible role in its metabolic regulation, and,
through its effects on the hepatic transsulfuration pathway, in the metabolic disposal
of this highly atherogenic amino acid. While the mode of insulin's action has yet to
be completely defined, insulin (along with counter-regulatory hormones) modulates
cystathionine fl-synthase gene transcription both in vitro and in vivo.
Chapter 5: The Glucagon-Treated Rat
,,,
5.1 Background
The regulatory effects of glucagon on amino acid metabolism arc weB known.
For example, in liver it can activate the glycine cleavage system, stimulate the l
transporter, and induce the five urea-cycle enzymes (Mabrouk et al., 1998;
Handlogten el al., 1984; Snodgrass el al., 1978). Patients with a glucagonoma have
diminished plasma amino acid levels which are related to increased clearance by the
liver (Barazzoni et al., 1999). In light of the broad effects of glucagon on amino acid
metabolism, it appears likely that homocysteine metabolism would be similarly
regulated, given that it is a product of the metabolism of dietary essential methionine,
and a precursor to cysteine. In addition, plasma glucagon is frequently elevated in
Type I diabetes (Unger, 1976; and Chapter 4). We therefore examined the role of
glucagon in regulating homocysteine metabolism in the rat.
5.2 The glucagon-treated rat
Glucagon treatment followed the procedure of Snod~,'Tass et al (1978).
Glucagon (2 mg/kglday, s.c.) was administered in 3 equal daily doses (at 0800, 1600,
2400) for 2 days while control rats received the vehicle (Hi Lilly Canada Inc).
Animals were fed a standard laboratory chow. Two hours following the last injection
rats were anaesthetized for plasma and tissue sampling (described in Chapter 2).
There were 3-8 rats in each experimental group. This study was perfonned in
collaboration with Lori Stead; thus some data also will be common to this thesis and
hers.
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5.3 Results
5.3.1 Alterations In plasma and liver amino acids following glucagon treatment
Table 5.1 gives infonnation on body weight, food intake, plasma glucose,
plasma insulin and plasma glucagon. Two day glucagon treatment did not affect
weight gain in male rats. Likewise, there was no change in food intake following
glucagon treatment. Thcrefore, none of the mctabolic changes observed can be
attributcd to alterations in vitamin or amino acid intakes. Plasma glucose was
increased by 80% (as expected) following glucagon administration. Plasma glucagon
was increascd 35-fold vcrsus control rats and there was no change in plasma insulin.
Total plasma homocysteine levels were decreased by 30% by glucagon
treatment (Table 5.2). This is the first report, to our knowledge, of the homocysteine
lowering effccts of glucagon. Table 5.2 also shows the effects of the glucagon
treatment on plasma and liver concentrations of the other amino acids involved in
sulfur amino acid metabolism. All plasma amino acids shown were significantly
decreased by glucagon-treatment. Hepatic amino acid levels are also reportcd. Liver
homocysteine and glycine levels were significantly decreased by glucagon treatment,
while the concentration of taurine was increased. No change was observed in the
hepatic levels of methionine. cysteine and serine. However, calculation of
intracellular amino acid concentrations revealed increased methionine and taurine in
the glucagon-treated rat, while intracellular homocysteine was decreased. Table 5.3
shows the effects of glucagon treatment on all of the plasma amino acids. All amino
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Table 5.1: Body weight, food intake, plasma glucose, insulin and glucagon
concentrations in control and glucagon-treated rats.
Units Cootrol Glucagon
Initial Weight 240± 15 245±7
Final Weight 272± 10 271 ±7
Food lntake glday 26.3±4.5 27.5±3.7
Plasma Glucagon pg/ml 79.5± 12.1 2630 ± 1040·
Plasma Insulin llglml 8.9± 1.7 7.1 ±2.6
Plasma Glucose mM 8.0±0.8 14.1 ± 1.3*
Rats were administered glucagon (4 mglkglday) for 2 days while control rats received
the vehicle. Food intake and body weight were measured daily. Blood samples were
taken from the abdominal aorta and centrifuged for plasma separation. Means ± SD
are shown for 3-6 rats. An asterisk signifies significant difference versus control rats,
P<O.05.
Table 5.2: Plasma and hepatic amino acids involved in homoC)'steine metabolism.
Control Glucagon
Plasma Liver Hepatic L:P Plasma Liver Uepatic L:P
(JIM) (nmol/mg) Intracellular Ratio (J11\1) (nmollmg) IntraccUular Ratio
concentration concentration
(I-lM) (PM)
Methionine 56.9±2.9 56.0± 6.0 94.1 ± 10.1 1.7 14.8±2.8- 60.6±6.0 125± 13- 8.5
Homocysteine 9.7± 1.1 9.0± 1.0 14.8± 1.7 1.5 6.4±0.7- 6.9± 1.0* 11.9± 1.7. 1.9
Cysteine 318±25 443± 110 808 ± 200 2.5 223±28- 358± 158 672 ±297 3.0
t; Taurine 177± 19 2850±435 6235±950 35 101± 18* 3600±557* 7943 ± 1228- 78
Serine 180:1:. 17 311 ±51 591 ±97 2.9 85 ±31· 330±48 686± 100 8.0
Glycine 239±38 920± 141 1912±293 8.0 96±34· 830 ± 77· 1804± 166 19.0
Plasma and liver amino acids were determined using a Beckman amino acid analyzer, except for total homocysteine and total
cysteine which wcre detcnnined by HPLC. Intracellular amino acid concentrations were calculated as described in Chapter 2.
Liver:Plasma (L:P) ratio is calculated by dividing the hcpatic intracellular amino acid concentration (J.LM) by the plasma amino
acid concentration (JlM) . Means ± standard deviation for 5 rats are shown. Asterisk indicates significant difference versus
control, P<0.05.
Table 5.3: Plasma amino acid levels in control and glucagon-treated rats.
Amino Acid
Trvptophan
Lysine
Glutamic Acid
Glutamine
Phenylalanine
Tyrosine
Histidine
Arginine
AspartleAcid
Asparagine
Threonine
Proline
Alanine
Valine
Isoleucine
Leucine
Citruline
Ornithine
Control
89 ±8.0
430±SZ
140±23
670±71
51 ± 5.0
86± 19
S9±9.0
210±2S
18±3.0
S3±6.0
303±30
196±6.0
480± 16
182±32
87± 18
130±20
88± 13
63±S.0
Glucagon
98± 16
38S±34
147± 1\.
37± to·
46± 13·
36±6·
101 ± 18·
lZ±6.0
13±2.0·
S7± 17·
3S±4.0·
113± 14·
lS4± 19
79± 12
60± IS·
38± IZ·
38± 10·
Amino acid concentrations are expressed as IltnollL and are presented as mean ± SO
(n"'S). An asterisk indicates significant difference from control (Student t·tcst,
P<O.OS).
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acids, except for tryptophan, aspartic acid, lysine, valine, and isoleucine, were
decreased in the hypcrglucagonemic rat. This general decrease in plasma amino acids
is consistent with observations made in the human glucagonoma patients (Barazzoni
etal.,1999).
53.2 Hepatocytcs Isolated from glucagon-treated rats export less homocysteine
The liver is the central organ in sulfur amino acid metabolism. It contains a
full complement of enzymes involved in the melhionil1e cycle and the transsulfuration
pathway and is thc site of 85% of all methylation reactions in the body (Wyss and
Wallimann, 1994). In light of this, it is reasonable to assume that alterations in
hepatic homocysteine metabolism would have a profound effect on circulating levels
of this atherogenic amino acid. We therefore measured homocysteine output by
isolated hepatocytcs. Previously, our lab has showed that the half-maximal rate of
homocysteine export occurs at a methionine concentration of 0.44 mM and is linear
for at least 60 minutes (Stead et al., 2000). A methionine concentration of I mM was
chosen for all experiments. Following incubation with methionine, hepatocytes
isolated from the glucagon-treated rats cxported less than half as much homocysteine
as the control hepatocytcs (Figure 5.1). Our earlier studies have shown that addition
of serine (a substrate for cystathionine [l-synthase), IOgether with methionine, reduced
homocysteine export (Stead et al., 2(00). We thereforc undertook experiments with
both serine and methionine in the incubation medium. Serine incubation decreased
ISO
Figure 5.1: Homocysteine export from bepatocytes isolated from
glucagon-treated and control rats. Hepatocytes were prcincuhated for 20 mins at 4-
6 mg dry weight of cells/ml in a final volwne of I ml in Krehs-Henseleit medium
containing 1.25 % BSA. Following preincubation, I mM methionine ± I mM serine
were added and incubation was allowed to continue for an additional 30 minutes.
Cells were gassed with 95% Dlf 5% COz at the beginning of the incubation and on
the addition of substrates. At the end of the incubation, the contents or the flasks were
centrifuged at 14000g for 2 minutes to sediment the cells. The supernatant was
removed for homocysteine analysis. Mean ± SD for 4 experiments is shown. Data
were analysed using ANQYA followed by Newman-Keuls multiple comparison post
test, with a P< 0.05 taken 10 indicate a significant difference. Results with differing
superscripts were significantly different from each other.
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homocysteine expon from the control hepalocytes by 50%. However serine did not
reduce, any funher, the homocysteine export by bepatocytes from glueagon.treated
animals. There was no change in the rate of cysteine export (1.5 nmoUmgl30 mins)
in any of the experimental groups.
5.3,3 Glucagon treatment increases hepatic enzyme activities invoh'ed i.n
methionine catabolism
Such a decrease in homocysteine expon by hepatocytes coupled with a
decreased intracellular homocysteine concentration suggests an appreciably altered
metabolism. We, therefore, assayed the major enzymes involved in producing
(transmethylation) and removing (transsu!furation and remethylation) homocysteine
in the liver. Glucagon-treated rats exhibited increased hepatic activities of enzymes
involved in the catabolism of methionine to cysteine (Table 5.4). The activities of
glycine N-methyltmnsferase and cystathionine y-Iyase were elevated by 25% while
cystathionine fl-synthase activity was increased by 90%. These changes arc still
evident when activities are expressed either as per gram liver or per 100 grams body
weight (data not shown). Methionine adenosyltransfcrasc activity was unaffected by
glucagon treatmen!. These data suggest the importance of the hepatic transsulfuration
pathway in glucagon's regulation of homocysteine metabolism. No changes were
observed in methionine synthase, betaine:homocysteine methyltransferase or
methy1cnetetrahydrofolate reductase activity.
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TABLE 5.4: i:Iepatie enzymes of methionine and homocysteine metabolism In
glucagon~treated rats
5-Adenosylmelhionine synthase
C)'stalhionine !l=synthase
Cystathionine y-Iyase
Glycine N-meth}'ltransferase
Methionine synthase
Betaine:homocystcinc methyltransferase
Methylcnctctrabydrofolate reductase
Conlrol
l.ZO±0.05
5.3 ±0.9
15.Z ±Z.O
1.0Z± 0.04
0.11 ±0.01
2.6±0.7
0.16 ±0.05
Glucagon
J.25±O.1O
9.3 ± I.Z*
19.6 ±3.Z*
I.Z5 ±0.1O*
0.11 ±O.OZ
2.2±O.1
O.14± 0.02
Liver samples were homogenized in potassium phosphate buffer and centrifuged at
17000g for 30 minutes. An assays were performed on the resulting POSI-
mitochondrial supernatant. Enzyme activity is expressed as nmol/mg protein/min.
Means ± SD for 6 rats arc shown. The asterisk indicates a significant difference
versus conrrol rats, P<O.05.
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5.3.4 mRNA levels in the glucagon.treated rats
We measured the mRNA levels for cystathionine 13-synthase and cystathionine
y-Iyase following glucagon treatment by comparing their abundance to that of13-actin.
Glucagon treatment increased cystathionine [3-synthase mRNA level by 90% (Figure
5.2). This increase is similar to the increase in enzyme activity. No change was
ob~rved in cystathionine y.lyase mRNA levels.
5.3.5 Allosteric regulators of cystathionine Il--synthase
Cystathionine 13-synthase can also be regulated allosterically by S-
adcnosylmethionine and S-adcnosylhomocystcine (Finkelstein el al., 1975). We
therefore measured the hepatic levels of these modulators. Hepatic concentrations of
both S-adenosylmethioninc and S-adenosylhomocysteinc were elevated following
glucagon administration (Figure 5.3). Howcvcr, the ratio of SAM:SAH, often
described as the "methylation ralio", was unchanged.
5.3.6 Increased nux through traossulluration foUowing glucagon treatment
Since increased enzyme activity alonc cannot be used as a measure of total
flux through the transsulfuration pathway, we devised a new method to measure thc
effect of glucagon !reatment on the Oux through the Iranssulfuration pathway in
hepalOcytes. The second step of the transsulfuration pathway involves the cleavage of
cystathionine to produce cysteine, NH/ and a.ketobutyrate (Refer to pathway in
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Figure 5.2: Northern Blot analysis of hepatic cystathionine Il·synthase and
cystathionine 'Y.1yase following glucagon treatment. Total RNA, isolated from
freeze-clamped livers, was separated on a 1% agarose/formaldehyde gcl and
transferred to a Nylon membrane. Cystathionine ~.synthasc (CIlS), cystathionine 'Y-
lyase (CyL) and Il-actin mRNA levels were determined by Nonhem Blot analysis
(shown in A). mRNA intensities were quantified by densitometry and normalized to
Il-aclin mRNA (shown in B). The data arc expressed as mean ± SD for 4 rats. The
asterisk signifies a difference between groups, 1'<0.05.
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Figure 5.3: S-adenosylmethionine, S·adl'nosylhomocysteine, and SAM/SAH
ratios in control and glucagon-treated rats. Freeze-clamped liver samples were
homogenized in 8% trichloroacetic acid. The samples were then centrifuged for 10
minutes at 13000£. S-adenosylmethionine and S~adenosylhomocystcinc were
determined by HPLC using UV dctection. Values are expressed as nmollg liver.
Means ± SO for 6 samples are shown. An asterisk indicates a significant difference
versus control, P<O.05.
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Figure 5.5). Incubating cells with L-[1-14C]methionine will give rise to a-[IYC]-
ketobutyrate which may be metabolized via pyruvate dehydrogenase to produce
14C02, which can be released with acid and readily collected and counted. Label in
unmetaboli7..ed a-[IYCl-ketobutyrate can be released with H202• Such 14C01,
released from a -ketobutyrate, must also be included in measures of flux through the
transsulfuration pathway (Wyss and Wallimann, 1994). Following incubation with L·
[1.14CJ-methionine there was a five-fold increase in 14C01 production from
hepatocytes isolated from the glucagon-treated rats as compared to control cells,
indicating a profound activation of flux through the transsulfuration pathway (Table
5.5). To ensure that 14C02 produced was actually a product of the transsulfuration
pathway, propargylglycine, an irreversible inhibitor of cyslathionine 'Y·lyase, was
included in the incubations. Blocking cystathionine 'Y·lyase resulted in an 80%
reduction in 14C02 production from hepatocytes isolated from control and glucagon·
treated rals, When hepatocytes were incubated with cyanocinnimate, an inhibitor of
the mitochondrialll·ketoacid transporter, there was a reduction in 14C02 released after
the addition of perehloric acid with a corresponding elevation of 14C02 release aller
addition of peroxide. These results further confinn 14C02 production from 1·14C•
methionine as a measure of flux through the transsulfuralion pathway and emphasize
the need to detennine 14C in u-ketobutyrate to fully quantify flux through this
pathway.
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5.3.7 Glucagon activates methionine transport in isolated hepatocytes
Our calculations show that the hepatic intracellular concentration of
methionine was elevated in the glucagon-treated rats (Table 5.2). Of particular
interest is that the ratio of liver cellular methionine to plasma methionine was five-
fold greater in the glucagon-treated animal. This could be explained by an effect of
glucagon on methionine transport. Methionine transport rates were, therefore,
measured from hepatocytes isolated from control and glucagon-treated rats. Glucagon
treatment resulted in a doubling of methionine uptake imo hepatocytes (Figure 5.4).
5.4 DISCUSSION
The regulatory effects of glucagon on amino acid metabolism have been well
documented. It increases the catabolism of a variely of amino acids (e.g. glycine,
glutamine, arginine, and phenylalanine), it increases gluconeogenesis from amino
acids, and it increases the ratc of ureagenesis (Mabrouk el at., 1998; Squires el al.,
1997; CalT and Pogson, 1981; O'Sullivan et aI., 2000, Wassennan et al., 1989; Meijer
el at., 1990). With this in mind, an investigation of the specific effects of glucagon on
homocysteine metabolism is warranted. The dose of glucagon used in this study was
indeed phannacological. Wc observed a 35-fold increase in plasma glucagon using
this dosage, well 3bovc circulating levels in control animals. Although these levels
are not observed in a healthy organism, patients with glucagon-producing tumours
have becn reported to havc GO-fold incre3se in plasma glucagon (Barazzoni et al..
1999). Therefore our model is a good reflection of human glucagonoma. This view is
Table 5.5: l4C02 and J-'4C-a.-ketobutyrate production by isolated hepatocytes incubated with I-C4q-methionine.
Control Gluca~on
Methionine
14C02 1_l4C-a_ Total l4COl 1}4C-a_ Total
ketobutyrate ketobutyrate
3.31±0.26 2.10±0.11 5.41±0.54 8.90±3.65 13.7±4.01 22.9±7.61
0.62 ± 0.12" 1.26 ± 0.11" 1.89 ± 0.20· 0.49 ± O.09bO 3.42 ± O.09bO 3.90 ± 0.20bOMethionine +
Propargyl!!;lycine
Methionine +
Cyanocinnimate
1.1 ±0.18" 4.17 ± 0.58" 5.27 ± 0.74 5.23± 1.93bO 24.2±3.l b• i9.9±4.99b"
Ri
Hepatocytcs werc preincubatcd for 20 minutes in BSA-supplemented Krebs-Henseleit medium and in the presence and
absence of propargylglycine (an inhibitor of CBS) and cyanocinnimate (an inhibitor of the mitochondrial ketoacid transporter).
Following the addition of I mM 1_[14C]_methionine the flasks were incubatcd for 30 minutes. The flasks were then equipped
with rubber septac in which plastic centre wells containing NCS tissue solublizer were suspended. Incubations were tenninated
bl injection of PCA and 14C0 2 was collected for I hour. Then a new centre well was added to the flask and H20 2was injected.
l CO2was collected for another hour and radioactivity measured. The total 14C02 produced was calculated by adding the 14C02
collected after the addition of PCA with the 14C02 collected after addition of H20 2. Data arc expressed as runol 14CO!
produeedlmg dry hepatocytesl 30 minutes. Means ± SO for 3 measurements arc shown.• P<0.05 versus same measurcmcnt in
control group (Student's t-test), a P<O.05 versus control cells incubated with methionine alone (Student's t-test), b P<O.05
versus glucagon cells incubated with methionine alone (Student's t-test)
Figure 5.4: Methionine transport in hepatocytes isolated from glucagon.
treated and control rats. Hepalocytes were preincubated for 20 mins at 4·6 mg dry
weight of cellsJml in a final volume of 2 ml in Krebs·Henseleit medium containing
1.25 % BSA. Following preincubation, l.l~C·methionine was added to a final
concentration of 0.5 mM. At designated time points I ml aliquots were transferred to
1.5 ml microcentrifuge tubes containing 0.25 ml silicone oil mixture layered on top of
0.1 m16% (vlv) perchloric acid. The tubes were centrifuged at 14000g for 15 seconds
to sediment cells through the silicone oil and into the acid layer. The tubes were
frozen in liquid nitrogen and then the tubes were cut at the end of the frozen silicone
oil layer. The radioactivity in the bottom layer was measured. Means ± SD are shown
for 4 experiments. The transport of methionine was linear in hepatocytes isolated
from both the control (y= 0.019x - 0.042, ~"" 0.78) and glucagon·treated (y"" 0.039x
- 0.002, r2"" 0.89) rats. An asterisk indicates a value significantly different (P<0.05)
from the corresponding control time point value.
.. Glucagon
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12030 60 90
Time (seconds)
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supported by the similar decreases in total and specific plasma amino acids in both
the glucagon-treated rat and the hwnan glucagonoma patient (Barazzoni et aI., 1999),
The decrease in amino acids in glucagonoma patients has been linked to increased
clearance from the plasma, likely by the liver, rather than 10 decreased export from
the muscles (Barazzoni et aI., 1999).
Regulation of the methionine cycle and of the transsulfuration pathway are
thought to be exerted primarily through alterations in substrate availability and in the
levels of the effector molecules, SAM and SAH. This work demonstrates, for the first
time, the effects of the catabolic hormone, glucagon, on these regulatory parameters
and on the expression of the rate-limiting !ranssulfuration enzyme, cystathionine Il-
synthase. Our in vj{ro and in vivo experiments show a dramatic effect of glucagon on
the metabolism of the atherogenic amino acid, homocysteine. It is clear, from our
data, that glucagon administration intervenes at a number of sites (reviewed in Figure
5.5) in methionine and homocysteine metabolism and, thus, the observed changes in
homocysteine arc a reflection of these different actions. Firstly, glucagon affects
methionine transport. This is evident from the fact that the hepatic intraceJlular
concentration of methionine was increased by 25% and, more impressively, that the
ratio of intracellular to plasma methionine was elevated 5-fold. This suggests a
marked stimulation of methionine transport into liver cells and, indeed, we found that
this was increased t\\'o-fold in the glucagon-treated rats. This is consistent with the
observation that glucagon up-regulates the System A amino acid transporter since this
'"
Figure 5.5: Effeds of glucagon on hepatic sulphur amino acid metabolism.
.,. Indicates elevation following glucagon treatment. ... Indicates reduction following
glucagon treatment. + Represents positive regulator of cystathionine ~-synthasc.
Key:
Transport Processes: (I) glucagon-sensitive methionine transporter; (2) reduced-
homocysteine carrier; (3) monocarboxylate Iransponer
Enzymes: (a) melhionine adenosyltransferase; (b) methyltransferases; (c) S-
adenosylhomocysteinc hydrolase; (d) betaine-homocysteine methyhransfcrase; (e)
methionine synthase; (f) cystathionine y-lyasc; (8) pyruvate dehydrogenase.
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is the major hepatic transportcr of methionine (McGivan and Pastor-Anglada, 1994).
Tt is likely that the incrcased hcpatic methionine level has important metabolic
consequences. In an elegant theoretical analysis of the control of hepatic methionine
metabolism, Martinov et al. (2000) showed that this system is eXlr'dordinarily
sensitive to small changes in methionine concentration, largely due to the kinetic
properties of the liver-specific S-adenosylmcthionine synthetase. Therefore, even in
the absence of a detectable increase in activity of this enzyme. it is expected that the
increased intracellular methionine cOllcentration will stimulate flux through S-
adenosylmcthionine synthase which can al:count for the increased hepatic SAM
levels.
The markedly decreased plasma methionine concentration, at a constant
dietary intake, implies increased methionine clearance, which is consistent with the
general plasma amino acid picture in our rat model, as wen as ;n human glucagonoma
patients. This would involve increased flux through glycine N-mcthyltransfcrase,
whose activity is modestly, though significantly. increased. S-adenosylhomocysteine.
produced in the glycinc N-methyllransferase reaction. is also increased in the livers of
these glucagon-treated rats. This may be partially as a result of the increased flux
though glycine N-methyltmnsferase but must also, in part, reOect its removal through
S-adenosylhomocysteinc hydrolase. This reaction is thought to operate close to
thennodynamic equilibrium in vivo (Kloor et 0/., (998). Since SAH levels are
increased and homocysteine levels are decreased after glucagon treatment, thc
maintenance of an equilibrium would require the concentration of adenosine, the
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other product of S-adcllosylhomocysteinc hydrolase, to be increased. However, we
did not examine this issue.
The increased hepatic SAM and SAH levels, alone, would tend to stimulate
flux through the transsulfuratioIl pathway, siIlce both of these nuc1eotides are
allostcric activators of cystathionine p-synthase. They both decrease cystathionine p..
synthase's Km for homocysteine (Finkelstein et aI., 1975). Howevcr, thc increased
maximal activities ofthe two enzymes of the transsulfuration pathway, especially that
of the rate-limiting cystathionine ~-synthase, also playa major role. Glucagon
treatment increased both cystathionine p-synthase activity and mRNA levels. This is
likely to be a result of a direct effect on the induction of cystathionine ~synthase.
Goss et al. (1986) showed that increased cAMP, glucagon's intracellular messenger,
leads to an increased cystathionine p-synthase activity in cultured hepatoma cells. As
mentioned in chapter 4, we have shown that cAMP increases cystathionine ~-synthase
mRNA in H4l1E cells. Insulin levels were unchanged in our glucagon-treated rats so
that changes in this hormone cannot account for the increased activity of
cystathionine ~synthase, although we have shown thai insulin treatment of diabetic
rats can reduce cystathionine ~-synthase activity to nonnal levels (Chapter 4). It is
currently unknown whether glucagon's effects on cystathionine p-synthase are
mediated by an increase in gene transcription, enhancement of mRNA stability, or
both. It has been reported that li,'er cystathionine p-synthase mRNA is increased in
rats fed a high-protein diet (yamamoto et al., 1996). Since such a diet is known to
elevate plasma glucagon (Peret et al., 1981) our results might provide an explanation
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for this dietary regulation of cystathionine l3-synthase. Furthermore, hepatic
transsulfuration flux and thus cysteine production is stimulatcd by a high protein
meal. This activation of the transsulfuration pathway may be mediated, in part, by the
physiological effects of glucagon.
That flux through the transsulfuration pathway is stimulated by glucagon
treatment is directly shown in isolated hepatocytes (Table 5.5). These data also
provide evidence that the u-ketobutyrate produced by cystathionine y-Iyase must enter
mitochondria on the mitochondrial ketoacid transporter for decarboxylation. A key
finding is that glucagon treatment caused a four-fold increase in flux through the
transsulfuration pathway even though the increased maximal activities of
cystathionine ~-synthase and cystathionine y-Iyase were less than two-fold. Clearly,
additional factors must playa role. In this context, the doubling of the rate of
methionine transport into the hepatocyte is key. It is possible that glucagon exerts
effects at other sites, sinee it activates cellular protein kinases. Cystathionine 13-
synthase docs contain a protein kinase A consensus sequencc but phosphorylation of
this enzyme has yet to be shown. We can eliminate the idea that flux through the
transsulfuration pathway is mediated by changes in serine, the co-substrate for
cystathionine ~-synthase. Indeed, hepatocytes isolated from the glucagon-treated rats
exported less homocysteine, when incubated with methionine, than did control
hepatocytes. When serine was included in the incubation, homocysteine export was
reduced in control hepatocytes but not in the hepatocytes isolated from glueagon-
treated rats. However, the possibility that such a mechanism is important in vivo is
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eliminated by the finding that the hepatic concentralion of serine was unaffected by
glucagon treatment.
The decreased plasma homocysteine, upon glucagon treatment, follows from
the decreased hepatic homocysteine concentration. Very littlc is known about the
transport of homocysteine across hepatocyte membranes. In rat cortical tubules
homocystine has been shown 10 share the y+ system transporter, with cystine and the
dibasic amino acids (Foreman ef a!., 1982). The uplake of homocystine is plausible
since most of the free homocysteine in plasma exists in an oxidized disulfide fonn.
However, uplake of homocystine by liver cells has not been reported. Furthennore,
since hepatocytes have such low activity of the y+ transporter another mechanism
may be required for homocyst(e)inc uplake (White, 1985). Given the reduced nature
of the intracellular milieu (The liver cytoplasmic NADPWNADpT ratio is about 100
and that ofOSH/OSSO is about 150 (Veech ef 01., 1969; Lakritz el at., 1997») most of
the intracellular homocysteine is believed to be in the reduced fonn. This necessitates
a transporter Ihal recognizes reduced homocysteine 10 effect homocysteine export. AI
present this carrier has not been identified. However, glucagon treatment caused no
change in the liver/plasma ratio for total homocysteine. Thus it appears that as hepatic
homocysteine fell, that in the plasma followed. II is not necessary to ascribe any role
10 changes in the homocysteine transporter.
Activated flux through the transsulfuralion pathway also requires increased
disposal of cysteine as this substance does not accumulate (Table 5.2). Pyruvate is the
carbon prodUCI of cysteine catabolism and is a good gluconcogcnic precursor. In view
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of glucagon's well-established role in stimulating gluconeogenesis and that
gluconeogenesis is the likely fate of much of our dietary amino acids (O'Sullivan et
al., 2000; Jungas el at., 1992) we suggest that glucose production is the carbon end-
product of cysteine oxidation in these glucagon-treated rats.
This chapter illustrates the effects of glucagon on sulfur amino acid
metabolism and provides a plausible explanation of how this catabolic hormone
affects circulating homocysteine concentrations. Our previous work (Chapter 4)
emphasized the role of insulin in regulating plasma homocysteine. Injection of this
anabolic hormone increases plasma homocysteine in the Type I diabetic rat. Taken
together it is clear that the opposing effects of these metabolic or "fuel" hormones can
be very important in controlling plasma homocysteine metabolism and that the livcr is
the site of this hormonal regulation.
Chapter 6: General Discussion and Conclusions
l7J
6.1 General Discussion
Elevated plasma bomocysteine is a well-established risk factor for the
development of vascular disease (Boushey et at., 1995). Both hypothyroid (Vanhac1st
et at., 1967) and diabetic (Ellenberg and Rifkin, 1990) patients have high incidence of
vascular disease, therefore much researcb has focused on the relationship between
these diseases and total plasma homocysteine. Several studies have described
increased plasma homocysteine concentrations in the hypothyroid patient (Nedrcbo et
aI., 1998; Hussein et at., 1999). Funhermore, homocysteine levels are normalized
when a euthyroid state is achieved (Hussein el al., 1999). Similarly, type 1 diabetes
mellitus patients have compromised homocysteine metabolism. Diabetic patients with
kidney dysfunction tend to exhibit increased plasma homocysteine (Hultberg et al.,
1991; Hultberg et al., 1997). On the other hand, type 1 diabetic patients wilh nomml
kidney function have decreased plasma homocysteine (Robillon et al., 1994; Cronin
et al., 1998). The mechanism for such perturbations was WlknOwn; however, we
hypothesized that hormonal regulation of homocysteine metabolism played an
important role in the regulation of this atherogenic amino acid. Therefore tbe
objective of this thesis was to investigate the effects of these hormones on
homocysteine metabolism using various rat models.
We have shown that the plasma levels of insulin, glucagon, and thyroid
hormone influence lotal plasma homocysteine concentrations in the rat. Our initial
purpose was to see if the diabetic ral mimics human type I diabetes with respect to
homocysteine. Indeed, the streptozotocin-diabetic ral exhibited decreased plasma
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homocysteine, as does the human patient (Robinon et af., 1994). Furthermore,
insulin-treatment raised plasma homocysteine in the diabetic rat. We also investigated
homocysteine metabolism in two hypothyroid rat models. Both hypothyroid rats
exhibited decreased total plasma homocysteine. This result contrasts with the human
sit.uation where hypothyroidism is associated with increased homocysteine levels
(Nedrcbo cf al., 1998). The reason for this discrepancy was not clear. It is possible
that the genes related to homocysteine metabolism respond differently to thyroid
hormone in rats as compared to humans. However, it is more likely attributed to
kidney dysfunction (Hussein et al., 1999), a common complication in hypothyroid
patients, that was not present in our rat models.
Although not immediately germane to our study, other hormones have been
shown to alter plasma homocysteine in humans. Several studies have reported that
men have higher homocysteine levels than women of childbearing years (B10m et a!.,
1988; Boers et af., 1983). Following menopause, when estrogen production has
ccased, women have Iligher homocystcine levcls thcn beforc menopausc (Bocrs et al.,
1983; Brattstrom et al., 1985). This increased plasma homocysteine was shown to be
normalized by estrogen replacement therapy (Mijatovic et af., 1998, Giri et af., 1998).
In an intcresting study in the Netherlands, Giltay et al. (1998) found decreased
homocysteine concentrations in male-to-female transsexuals who received estrogen
and antiandrogen treatment. Taken together, the human studies suggest that sex
hormones influence plasma homocysteinc, however, the mechanism for such
regulation has yet to be established. Preliminary studies using male rats have shown
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that administration of estradiol or cortisol reduces plasma homocysteine (Kim el af.,
1997). Since these hormones influence each other's receptor system (8unone et af.,
1996) and male rats lack female sex organs, one could postulate that these steroid
hormones regulate plasma homocysteine by a similar mechanism. We have shown
that glucocorticoids induce cystathionine ~-synthase in rat hepatoma cells. It is
possible thai stimulation of the transsulfuration pathway may explain the sterol·
induced decrease in plasma homocysteine. Further study is needed to detennine if
hepatic CBS is influenced by in vivo perturbations of glucocorticoid levels.
Similarly, the role of estrogen in regulating homocysteine catabolis~ requires funher
study.
Many clinical studies have shown a positive correlation between insulin and
plasma homocysteine levels (GalJistJ et 01., 2000; Robillon el al., 1994; Meigs el at.,
200 I). In agreement with the assumption that insulin raises homocysteine levels, we
have demonstrated an increased activity of hepatic transsulfuration enzymes and
concurrent decreased homocysteine levels in the slrcptozotoein-induced diabetic rat.
This effect was reversed by insulin treatment. The in vivo effect of insulin was, at
least in part, due to suppression of hepatic cystathionine p-synthase gene expression.
To support our in vivo data, we showed, for the first time, the direct stimulation of
CBS gene transcription by glucocorticoids and cAMP (a second messenger of
glucagon) in rat hepatoma cells. The finding that insulin antagonized this stimulation
of CBS is consistent with the fact thaI the actions of glucocorticoids and glucagon in
the regulation of protein, carbohydrate, and lipid metabolism are commonly opposed
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by insulin (O'Brien etal., 1991; Haunere/ at., 1987; Nebes and Morris, 1988). A role
of insulin in regulating human CBS has recenOy been shown in human hepatoma
cells. Insulin treatment reduced CBS activity by 70% in HepG2 cells (Ratnam et al.,
2002). The mechanism of insulin's action was investigated by fusing the CBS gene-
promoter to a luciferase-reporter gene. Treatment of lransfected cells with insulin
resulted in a massive decrease in luciferase activity thereby showing that insulin
decreases CBS activity through insulin sensitive sequences on the CBS gene. These
results provide evidence that the hormonal regulation of CBS is similar in human and
rodents (Ratnam el at., 2002).
The role of cystathionine ll-synthase in regulating plasma homocysteine levels
is evident in mice and humans. Watanabe et a!. (1995) have shown that transgenic
mice, heterozygous for a mutant cystathionine !l-synthase, have only half the normal
activity of this enzyme and twice the normal plasma homocysteine level, while
Down's syndrome patients, who have an extra allele of the cystathionine Il-synthase
gcne, tend to have very low plasma homocysteine concentrations (Brattstrom e/ at.,
1989). Furthermore, the results from our glucagon-treated rat have provided evidence
for the role of hepatic CBS in regulating plasma homocysteine. Glucagon
administration increased hepatic CBS mRNA, activity and flux resulting in decreased
plasma homocystcine concentrations in the rat.
From our in vivo and in vitro experiments we can postulate a physiological
role for insulin and glucagon in regulating homocysteine metabolism. It seems that
methionine is conserved during insulin excess. The extra methionine may be required
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as a substrate for protein synthesis, which is stimulated by elevated insulin levels. In
contrast, when methionine is in excess, such as after a high protein meal, there is an
increase in hepatic transsulfuration flux (Finkelstein and Martin, 1986). This is
relevant since pla<;ma glucagon levels are elevated following a high protein meal
(Linn el al., 2000). It is not inconceivable that the combined actions of insulin and
glucagon provide the underlying mechanism for altered hepatic transsulfuration flux
in response to dietary changes. It is also likely that the transsulfuration pathway is
activated in parallel with gluconeogenesis since the product of the transsulfuration
pathway, pyruvate, is an important gluconeogenic precursor. In addition, the
honnonal regulation of cystathionine ~syntbasc is similar to that of
phosphoenolpyruvate carboxykinase, the rate-limiting step in gluconeogenesis
(Sasaki et aI., 1984). Further evidence arises from diabetic (Hargrove el al., 1989) and
hyperglucagonemic rats (Chapter 5). Both models have elevated flux through Ihe
transsulfuration and gluconeogcnic pathways (Noguchi el aI., 1993).
The role of glueocorticoids in regulating sulfur amino acid metabolism may
be related to stress or trauma. It has been shown that whole body methionine
catabolism and glutathione production was increased in the septic rat (Malmezal el
al., 2000). In hepatoma cells, glutathione production was increased during oxidative
stress with 50% of the glutathione's cysteine derived from homocysteine (Mosharov
et aI., 2000). It is possible that glueocorticoids, which are elevated during sepsis,
stimulate methionine catabolism, through actions on MAT (Gil el al., 1997) and CBS,
in order to increase production of cysteine (an important substrate in glutathione
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production). In such situations maintenance of the glutathione pool may be vital to
limiting oxidative damage.
6.2 Conclusions
The central theme of this thesis is the honnonal regulation of homocysteine
metabolism. Using in vivo and in vitro techniques we made the following key
observations and conclusions:
I. Total plasma homocysteine is reduced in two rat models of hypothyroidism. This
decrease in plasma homocysteine was associated with increased hepatic activity of
the transsulfuration enzymes as compared to their respective controls. In addition,
thyroid replacement therapy to thyroidectomized rats nonnalized both plasma
homocysteine and hepatic enzyme activities. These results suggest th:!t alterations in
the hepatic transsulfuration may contribute to plasma homocysteine levels in the
hypothyroid rat. In our studies the rat did not mimic the buman situation and therefore
cannot be used as a model to study homocysteine metabolism in the hypothyroid
patient.
(Jacobs RL, Stead LM, Brosnan ME, and Brosnan JT (2000) Can J Phys and
Pharm. 78, 565-570)
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2. The streptozotocin-induced diabetic rat exhibit decreased plasma homocysteine as
docs the human type I diabetic patient. This decrease in plasma homocysteine was
reversed (partially or completely) by insulin-treatment. The hepatic activities of
enzymes responsible for converting methionine to cysteine were increased in the
untreated-diabetic rat. These changes were nonnalized by insulin-treatment.
Therefore, it is likely that increased hepatic catabolism of homocysteine is
responsible for the decrease in plasma homoc}'1iteine observed in the untreatcd-
diabetic rat.
(Jacobs RL, House JD, Brosnan ME, and Brosnan JT. (1998) Diabetes. 47:1967-
1970)
3. Increased renal homocysteine catabolism cannot be responsible for the decreased
plasma homocysteine in the diabetic rat. This conclusion is supported by two lines of
evidence: first, the renal activities of the transsulfuration enzymes were not elevated
in the untreated-diabetic rat and second, the proportion of plasma homocysteine
metabolized by the kidney in vivo was not altered by slreptozotocin-administration.
(Jacobs RL, House JD, Brosnan ME, and Brosnan JT. (1999) Diabetes. 47:1967·
1970 and unpublished data)
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4. Hepatic cystathionine p-synthase mRNA levels were elevated in the untreated-
diabetic rat. This induction was reversed by insulin within I day of treatment. Studies
using H411E cells provide convincing evidence for the direct suppression of CBS
gene transcription by insulin and its induction by counter-regulatory effectors (such
as glucocorticoids and c.AMP). By measuring CBS activity, protein concentrations
and mRNA levels in rat hepatoma cells we showed that the action of insulin is
dominant over the othcr honnoncs.
(Ratnam S. Mclean K, Jacobs RJ, Brosnan, ME Kraus J, and Brosnan JT.
(2002) J Bioi Chern. ePub Aug 26.)
6. Hyperglucagonemic rats exhibited decrease<! total plasma homocysteine levels.
This was the first report to show a role for glucagon in regulating plasma
homocysteine concentration.
7. We have provided a detailed explanation how glucagon stimulates hepatic sulfur-
amino acid catabolism resulting in decreased plasma homocysteine levels. Hepatic
activities of the transsulfuration enzymes were elevated by glucagon treatment. When
incubated with methionine, hepatocytes isolated from glucagon-treated animals
exported less homocysteine and converted more methionine to cystathionine than did
control cells. This increased flux through CBS may be explained by increased hepatic
transport of methionine. which raised the hepatic levels of important allosteric
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regulators of CBS (S·adenosylmethionine and S-adenosylhomocysteinc). These
results indicate that glucagon can regulate plasma homocysteine through the effects
on the hepatic transsulfuration pathway.
(Jacobs RL, Stead LM. Brosnan ME, and Brosnan JT (2001) J Bioi Chern
276:43740-43747)
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